Evofem Biosciences (EVFM) 10-Q 15 May 24 2024 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2024	May 10, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-36754
Entity Registrant Name	EVOFEM BIOSCIENCES, INC.
Entity Central Index Key	0001618835
Entity Tax Identification Number	20-8527075
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	7770 Regents Road
Entity Address, Address Line Two	Suite 113-618
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92122
City Area Code	(858)
Local Phone Number	550-1900
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	EVFM
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		62,060,395

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents
Restricted cash	689	580
Trade accounts receivable, net	4,306	5,738
Inventories	1,306	1,697
Prepaid and other current assets	622	1,195
Total current assets	6,923	9,210
Property and equipment, net	1,200	1,203
Operating lease right-of-use assets	59	106
Other noncurrent assets	35	35
Total assets	8,217	10,554
Current liabilities:
Accounts payable	16,294	17,020
Accrued expenses	4,575	4,227
Accrued compensation	3,261	2,609
Operating lease liabilities-current	55	97
Derivative liabilities	4,310	1,926
Other current liabilities	3,391	3,316
Total current liabilities	74,239	72,463
Operating lease liabilities- noncurrent	4	8
Total liabilities	74,243	72,471
Commitments and contingencies (Note 7)
Convertible and redeemable preferred stock, $0.0001 par value, Senior to common stock
Series E-1, and F-1 convertible preferred stock, 2,300 and 95,000 shares authorized; 1,921 and 1,874 shares of E-1 issued and outstanding at March 31, 2024 and December 31, 2023, respectively; 22,280 shares of F-1 issued and outstanding at each of March 31, 2024 and December 31, 2023	4,640	4,593
Stockholders’ deficit:
Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding at March 31, 2024 and December 31, 2023
Common Stock, $0.0001 par value; 3,000,000,000 shares authorized; 48,710,395 and 20,007,799 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	5	2
Additional paid-in capital	823,409	823,036
Accumulated other comprehensive loss	(525)	(849)
Accumulated deficit	(893,555)	(888,699)
Total stockholders’ deficit	(70,666)	(66,510)
Total liabilities, convertible and redeemable preferred stock and stockholders’ deficit	8,217	10,554
Baker Bros. Notes [Member]
Current liabilities:
Convertible notes	13,252	14,731
Adjuvant Notes [Member]
Current liabilities:
Convertible notes	$ 29,101	$ 28,537

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Convertible preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares Issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	3,000,000,000	3,000,000,000
Common stock, shares issued	48,710,395	20,007,799
Common stock, shares outstanding	48,710,395	20,007,799
Series E-1 Convertible and Redeemable Preferred Stock [Member]
Convertible preferred stock, shares authorized	2,300	2,300
Convertible preferred stock, shares issued	1,921	1,874
Convertible preferred stock, shares outstanding	1,921	1,874
Series F-1 Convertible and Redeemable Preferred Stock [Member]
Convertible preferred stock, shares authorized	95,000	95,000
Convertible preferred stock, shares issued	22,280	22,280
Convertible preferred stock, shares outstanding	22,280	22,280

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Product sales, net	$ 3,603	$ 5,809
Operating Expenses:
Cost of goods sold	684	1,376
Research and development	594	540
Selling and marketing	2,345	3,854
General and administrative	2,824	3,618
Total operating expenses	6,447	9,388
Loss from operations	(2,844)	(3,579)
Other income (expense):
Interest income	4	18
Other expense, net	(616)	(318)
Loss on issuance of financial instruments (Note 8)	(3,275)	(84)
Gain on debt extinguishment	1,120
Change in fair value of financial instruments (Note 6)	802	1,612
Total other income (expense), net	(1,965)	1,228
Loss before income tax	(4,809)	(2,351)
Income tax expense		(3)
Net loss	(4,809)	(2,354)
Convertible preferred stock deemed dividends	(47)
Net loss attributable to common stockholders	$ (4,856)	$ (2,354)
Net loss per share attributable to common stockholders
Earnings per share - basic	$ (0.16)	$ (1.85)
Earnings per share - diluted	$ (0.16)	$ (1.85)
Weighted-average shares used to compute net
loss per share attributable to common shareholders - basic	31,194,393	1,271,524
loss per share attributable to common shareholders - diluted	31,194,393	1,271,524

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Net loss	$ (4,809)	$ (2,354)
Other comprehensive income:
Change in fair value of financial instruments attributed to credit risk change (Note 4)	324	15,460
Comprehensive income (loss)	$ (4,485)	$ 13,106

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Convertible and Redeemable Preferred Stock and Stockholders' Deficit (Unaudited) - USD ($) $ in Thousands	Series E-1 Convertible and Redeemable Preferred Stock [Member] Preferred Stock [Member]	Series E-1 Convertible and Redeemable Preferred Stock [Member]	Series F-1 Convertible and Redeemable Preferred Stock [Member] Preferred Stock [Member]	Series F-1 Convertible and Redeemable Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance ,value at Dec. 31, 2022						$ 817,367	$ 49,527	$ (938,694)	$ (71,800)
Common stock, Balance, shares at Dec. 31, 2022					984,786
Issuance of common stock upon cash exercise of warrants						67			67
Issuance of common stock upon cash exercise of warrants, shares					24,200
Issuance of common stock upon noncash exercise of Purchase Rights (Note 4)						180			180
Issuance of common stock upon noncash exercise of Purchase Rights, shares					718,704
Stock-based compensation						417			417
Change in fair value of financial instruments attributed to credit risk change (Note 4)							15,460		15,460
Net loss								(2,354)	(2,354)
Issuance of SSNs (Note 4)						1,629			1,629
Balance ,value at Mar. 31, 2023						819,660	64,987	(941,048)	(56,401)
Common stock, Balance, shares at Mar. 31, 2023					1,727,690
Balance ,value at Dec. 31, 2023	$ 1,874		$ 2,719		$ 2	823,036	(849)	(888,699)	$ (66,510)
Temporary equity, beginning balance, shares at Dec. 31, 2023	1,874	1,874	22,280	22,280
Common stock, Balance, shares at Dec. 31, 2023					20,007,799				20,007,799
Issuance of common stock upon cash exercise of warrants						15			$ 15
Issuance of common stock upon cash exercise of warrants, shares					246,153
Issuance of common stock upon noncash exercise of Purchase Rights (Note 4)					$ 2	87			89
Issuance of common stock upon noncash exercise of Purchase Rights, shares					17,725,000
Issuance of common stock upon conversion of notes					$ 1	34			35
Issuance of common stock upon conversion of notes, shares					10,731,443
Stock-based compensation						237			237
Change in fair value of financial instruments attributed to credit risk change (Note 4)							324		324
Series E-1 shares dividends	$ 47							(47)	(47)
Series E-1 Shares dividends, shares	47
Net loss								(4,809)	(4,809)
Balance ,value at Mar. 31, 2024	$ 1,921		$ 2,719		$ 5	$ 823,409	$ (525)	$ (893,555)	$ (70,666)
Temporary equity,ending balance, shares at Mar. 31, 2024	1,921	1,921	22,280	22,280
Common stock, Balance, shares at Mar. 31, 2024					48,710,395				48,710,395

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net loss	$ (4,809)	$ (2,354)
Adjustments to reconcile net loss to net cash, cash equivalents and restricted cash provided by (used in) operating activities:
Loss on issuance of financial instruments	3,275	84
Change in fair value of financial instruments	(802)	(1,612)
Gain on debt extinguishment	(1,120)
Stock-based compensation	237	417
Depreciation	12	245
Noncash interest expense	564	565
Noncash right-of-use amortization	47	504
Net loss on disposal of property and equipment	5
Changes in operating assets and liabilities:
Trade accounts receivable	1,432	(6,278)
Inventories	391	(99)
Prepaid and other assets	573	1,518
Accounts payable	(726)	3,813
Accrued expenses and other liabilities	438	(352)
Accrued compensation	652	(800)
Operating lease liabilities	(46)	(591)
Net cash and restricted cash provided by (used in) operating activities	123	(4,940)
Cash flows from investing activities:
Purchases of property and equipment	(14)	(3)
Net cash and restricted cash used in investing activities	(14)	(3)
Cash flows from financing activities:
Proceeds from issuance of common stock - exercise of warrants		61
Borrowings under term notes		1,640
Net cash and restricted cash provided by financing activities		1,701
Net change in cash, cash equivalents and restricted cash	109	(3,242)
Cash, cash equivalents and restricted cash, beginning of period	580	4,776
Cash, cash equivalents and restricted cash, end of period	689	1,534
Supplemental disclosure of noncash investing and financing activities:
Issuance of common stock upon exercise of purchase rights	89	180
Purchases of property and equipment included in accounts payable and accrued expenses	78	140
Series E-1 shares deemed dividends	47
Issuance of common stock upon conversion of notes	35
Issuance of common stock upon exercise of warrants	15
Financing costs included in accounts payable and accrued expenses		$ 125

Description of Business and Bas

Description of Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Description of Business and Basis of Presentation	Description of Business and Basis of Presentation Description of Business Evofem is a San Diego-based, commercial-stage biopharmaceutical company committed to commercializing innovative products to address unmet needs in women’s sexual and reproductive health. The Company’s first commercial product, Phexxi ® 16.8 18.2 On December 11, 2023, the Company entered into an Agreement and Plan of Merger, as amended (the Merger Agreement) with Aditxt, Inc., a Delaware corporation (Aditxt) and Adifem, Inc. (f/k/a Adicure, Inc.), a Delaware corporation, and a wholly-owned Subsidiary of Aditxt (Merger Sub), pursuant to which, and on the terms and subject to the conditions thereof, the Merger Sub was expected to merge with and into the Company, with the Company surviving as a wholly owned subsidiary of Aditxt (the Merger). As discussed in Note 10 – Subsequent Events Note 10 – Subsequent Events Basis of Presentation and Principles of Consolidation The Company prepared the unaudited interim condensed consolidated financial statements included in this Quarterly Report in accordance with accounting principles generally accepted (GAAP) in the United States for interim financial information and the rules and regulations of the Securities and Exchange Commission (SEC) related to quarterly reports on Form 10-Q. The Company’s financial statements are presented on a consolidated basis, which include the accounts of the Company and its wholly-owned subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation. The unaudited interim condensed consolidated financial statements do not include all information and disclosures required by GAAP for annual audited financial statements and should be read in conjunction with the Company’s condensed consolidated financial statements and notes thereto for the year ended December 31, 2023 included in its Annual Report on Form 10-K as filed with the SEC on March 27, 2024 (the 2023 Audited Financial Statements). The unaudited interim condensed consolidated financial statements included in this report have been prepared on the same basis as the Company’s audited consolidated financial statements and include all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position, results of operations, cash flows, and statements of convertible and redeemable preferred stock and stockholders’ deficit for the periods presented. The results for the three months ended March 31, 2024 are not necessarily indicative of the results expected for the full year. The condensed consolidated balance sheet as of December 31, 2023 was derived from the 2023 Audited Financial Statements. Risks, Uncertainties and Going Concern Any disruptions in the commercialization of Phexxi and/or its supply chain could have a material adverse effect on the Company’s business, results of operations and financial condition. The condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities, in the normal course of business, and does not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from the outcome of this uncertainty. The Company’s principal operations are related to the commercialization of Phexxi. Additional activities have included raising capital, identifying alternative manufacturing to lower the cost of goods sold (COGS), seeking ex-U.S. licensing partners and product in-licensing/acquisition opportunities to add non-dilutive capital to the balance sheet, and establishing and maintaining a corporate infrastructure to support a commercial product. The Company has incurred operating losses and negative cash flows from operating activities since inception. As of March 31, 2024, the Company a working capital deficit of $ 67.3 million and an accumulated deficit of $ 893.6 million. Since October 3, 2022, the Company’s common stock has traded on the OTC Venture Market (the OTCQB) of the OTC Markets Group, Inc., a centralized electronic quotation service for over-the-counter securities, under the symbol “EVFM.” The OTCQB imposes, among other requirements, a minimum $ 0.01 0.01 0.0136 Management’s plans to meet its cash flow needs in the next 12 months include generating recurring product revenue, restructuring its current payables, and obtaining additional funding through means such as the issuance of its capital stock, non-dilutive financings, or through collaborations or partnerships with other companies, including license agreements for Phexxi in the U.S. or foreign markets, or other potential business combinations. The Company anticipates it will continue to incur net losses for the foreseeable future. According to management estimates, liquidity resources as of March 31, 2024 were not sufficient to maintain the Company’s cash flow needs for the twelve months from the date of issuance of these condensed consolidated financial statements. If the Company is not able to obtain the required funding through a significant increase in revenue, equity or debt financings, license agreements for Phexxi in the U.S. or foreign markets, or other means, or is unable to obtain funding on terms favorable to the Company, or if there is another event of default affecting the notes payable, there will be a material adverse effect on commercialization operations and the Company’s ability to execute its strategic development plan for future growth. If the Company cannot successfully raise additional funding and implement its strategic development plan, the Company may be forced to make further reductions in spending, including spending in connection with its commercialization activities, extend payment terms with suppliers, liquidate assets where possible at a potentially lower amount than as recorded in the condensed consolidated financial statements, suspend or curtail planned operations, or cease operations entirely. Any of these could materially and adversely affect the Company’s liquidity, financial condition and business prospects, and the Company would not be able to continue as a going concern. The Company has concluded that these circumstances and the uncertainties associated with the Company’s ability to obtain additional equity or debt financing on terms that are favorable to the Company, or at all, and otherwise succeed in its future operations raise substantial doubt about the Company’s ability to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the notes thereto. Significant estimates affecting amounts reported or disclosed in the condensed consolidated financial statements include, but are not limited to: the assumptions used in measuring the revenue gross-to-net variable consideration items; the trade accounts receivable credit loss reserve estimate; the assumptions used in estimating the fair value of convertible notes, preferred stock, warrants and purchase rights issued; the assumptions used in the valuation of inventory; the useful lives of property and equipment; the recoverability of long-lived assets; and the valuation of deferred tax assets. These assumptions are more fully described in Note 3 – Revenue Note 4 – Debt Note 6 - Fair Value of Financial Instruments Note 7 - Commitments and Contingencies Note 9 - Stock-based Compensation Segment Reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker, the Chief Executive Officer of the Company, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment. Concentrations of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. Deposits in the Company’s checking, time deposit and investment accounts are maintained in federally insured financial institutions and are subject to federally insured limits or limits set by Securities Investor Protection Corporation. The Company invests in funds through a major U.S. bank and is exposed to credit risk in the event of default to the extent of amounts recorded on the condensed consolidated balance sheets. The Company has not experienced any losses in such accounts and believes it is not exposed to significant concentrations of credit risk on its cash, cash equivalents and restricted cash balances on amounts in excess of federally insured limits due to the financial position of the depository institutions in which these deposits are held. The Company is also subject to credit risk related to its trade accounts receivable from product sales. Its customers are located in the U.S. and consist of wholesale distributors, retail pharmacies, and mail-order specialty pharmacies. The Company extends credit to its customers in the normal course of business after evaluating their overall financial condition and evaluates the collectability of its accounts receivable by periodically reviewing the age of the receivables, the financial condition of its customers, and its past collection experience. Historically, the Company has not experienced any credit losses. As of March 31, 2024, based on the evaluation of these factors the Company did not record an allowance for doubtful accounts. Phexxi is distributed primarily through three major distributors and mail-order pharmacies, who receive service fees calculated as a percentage of the gross sales, and a fee-per-unit shipped, respectively. These entities are not obligated to purchase any set number of units. They distribute Phexxi on demand as orders are received. For the three months ended March 31, 2024, and 2023, the Company’s three largest customers combined made up approximately 82 % and 86 % of its gross product sales, respectively. As of March 31, 2024 and December 31, 2023, the Company’s three largest customers combined made up 89 % and 87 %, respectively, of its trade accounts receivable balance. Significant Accounting Policies There have been no changes to the significant accounting policies that were described in Note 2 – Summary of Significant Accounting Policies of the 2023 Audited Financial Statements in the Company’s Annual Report. Cash, Cash Equivalents and Restricted Cash Cash and cash equivalents consist of readily available cash in checking accounts and money market funds. Restricted cash consists of cash held in monthly time deposit accounts and letters of credit as described in Note 7- Commitments and Contingencies 0.3 25.0 0.8 The following table provides a reconciliation of cash, cash equivalents and restricted cash, reported within the condensed consolidated statements of cash flows (in thousands): Schedule of Reconciliation of Cash and Restricted Cash 2024 2023 Three months ended March 31, 2024 2023 Cash and cash equivalents $ - $ 639 Restricted cash 689 895 Total cash, cash equivalents and restricted cash presented in the condensed consolidated statements of cash flows $ 689 $ 1,534 Net Loss Per Share Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. The net loss available to common stockholders is adjusted for amounts in accumulated deficit related to the deemed dividends triggered for certain financial instruments. Such adjustment was immaterial and zero in the three months ended March 31, 2024 and 2023, respectively. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, potentially dilutive securities are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for the three months ended March 31, 2024 and 2023. Potentially dilutive securities excluded from the calculation of diluted net loss per share are summarized in the table below. Common shares were calculated for the convertible preferred stock and the convertible debt using the if-converted method. Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share 2024 2023 Three months ended March 31, 2024 2023 Options to purchase common stock 3,747 4,843 Warrants to purchase common stock 20,807,543 3,180,282 Purchase rights to purchase common stock 1,530,645,242 14,238,827 Convertible debt 2,430,230,049 18,042,988 Series E-1 and F-1 preferred stock 1,531,629,677 - Total (1) 5,513,316,258 35,466,940 (1) The potentially dilutive securities in the table above include all potentially dilutive securities that are not included in the diluted EPS as per U.S. GAAP, whereas the total common stock reserved for future issuance in Note 8 – Stockholders’ Deficit Recently Adopted Accounting Pronouncements No significant new standards have been adopted during the three months ended March 31, 2024. Recently Issued Accounting Pronouncements — Not Yet Adopted From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standards setting bodies that are adopted as of the specified effective date. In November 2023, the FASB issued ASU No. 2023-07, Improvements to Reportable Segment Disclosures In December 2023, the FASB issued ASU No. 2023-09, Income Taxes: Improvements to Income Tax Disclosures The Company does not believe the impact of any other recently issued standards and any issued but not yet effective standards will have a material impact on its condensed consolidated financial statements upon adoption.

Revenue

Revenue	3 Months Ended
	Mar. 31, 2024
Revenue from Contract with Customer [Abstract]
Revenue	Revenue The Company recognizes revenue from the sale of Phexxi in accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers In accordance with ASC 606, the Company recognizes revenue when its performance obligation is satisfied by transferring control of the product to a customer. In accordance with the Company’s contracts with customers, control of the product is transferred upon the conveyance of title, which occurs when the product is sold to and received by a customer. The Company’s customers are located in the U.S. and consist of wholesale distributors, retail pharmacies, and mail-order specialty pharmacies. Payment terms typically range from 31 66 The amount of revenue recognized by the Company is equal to the amount of consideration that is expected to be received from the sale of product to its customers. Revenue is only recognized when the performance obligation is satisfied. To determine whether a significant reversal will occur in future periods, the Company assesses both the likelihood and magnitude of any such potential reversal of revenue. Phexxi is sold to customers at the wholesale acquisition cost (WAC) or, in some cases, at a discount to WAC. However, the Company records product revenue net of reserves for applicable variable consideration. These types of variable consideration reduce revenue and include the following: ● Distribution services fees ● Prompt pay and other discounts ● Product returns ● Chargebacks ● Rebates ● Patient support programs, including our co-pay programs An estimate for variable consideration is made with each sale and is recorded in conjunction with the revenue being recognized. To calculate the variable consideration, the Company uses the expected value method and the estimated amounts are recorded as a reduction to accounts receivable or as a current liability based on the nature of the allowance and the terms of the related arrangements. An estimated amount of variable consideration may differ from the actual amount. At each balance sheet date, these provisions are analyzed and adjustments are made if necessary. Any adjustments made to these provisions would also affect net product revenue and earnings. In accordance with ASC 606, the Company must make significant judgments to determine the estimate for certain variable consideration. For example, the Company must estimate the percentage of end-users that will obtain the product through public insurance, such as Medicaid, versus private commercial insurance. To determine these estimates, the Company relies on historical sales data showing the amount of various end-user consumer types, inventory reports from the wholesale distributors and mail-order specialty pharmacies, and other relevant data reports. The specific considerations that the Company uses in estimating these amounts related to variable consideration are as follows: Distribution services fees Prompt pay and other discount The Company may also give other discounts to its customers to incentivize purchases and promote customer loyalty. The terms of such discounts may vary by customer. These discounts reduce gross product revenue at the time the revenue is recognized. Chargebacks Rebates Patient support programs Product returns The variable considerations discussed above were recorded in the condensed consolidated balance sheets and consisted of $ 0.2 0.3 3.2

Debt

Debt	3 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
Debt	Debt Convertible Notes Baker Bros. Notes (temporarily owned by Aditxt from December 11, 2023 through February 26, 2024) On April 23, 2020, the Company entered into a Securities Purchase and Security Agreement (the Baker Bros. Purchase Agreement) with certain affiliates of Baker Bros. Advisors LP, as purchasers (the Baker Purchasers), and Baker Bros. Advisors LP, as designated agent, pursuant to which the Company agreed to issue and sell to the Baker Purchasers (i) convertible senior secured promissory notes (the Baker Notes) in an aggregate principal amount of up to $ 25.0 25.0 2,731 4,575 five-year The Baker Notes had a five-year 10.0 10.0 2.5 1.4 The Baker Notes were callable by the Company on 10 100 9,356.25 110 4,575 On November 20, 2021, the Company entered into the first amendment to the Baker Bros. Purchase Agreement (the First Baker Amendment), in which each Baker Purchaser had the right to convert all or any portion of the Baker Notes into common stock at a conversion price equal to the lesser of (a) $ 4,575 115 115 50 The First Baker Amendment also extended, effective upon the Company’s achievement of the Financing Threshold, the affirmative covenant to achieve $ 100.0 582,886 93.75 Note 8 – Stockholders’ Deficit 0.0158 0.0154 Note 10 – Subsequent Events On March 21, 2022, the Company entered into the second amendment to the Baker Bros. Purchase Agreement (the Second Baker Amendment), which granted each Baker Purchaser the right to convert all or any portion of the Baker Notes into common stock at a conversion price equal to the lesser of (a) $ 725.81 100 100 20 EVOGUARD 93.75 100.0 On September 15, 2022, the Company entered into the third amendment to the Baker Bros. Purchase Agreement (the Third Baker Amendment), pursuant to which the conversion price was amended to $ 26.25 two-year On December 19, 2022, the Company entered into the First Amendment to the Forbearance Agreement (the Amendment) effective as of December 15, 2022 to amend certain provisions of the Forbearance Agreement dated September 15, 2022. The Amendment revised the Forbearance Agreement to (i) amend the Fifth Recital Clause to clarify that the Purchasers consent to any additional indebtedness pari passu 5.0 On March 7, 2023, Baker Bros. Advisors, LP (the Designated Agent) provided a Notice of Event of Default and Reservation of Rights (the Notice of Default) relating to the Baker Bros. Purchase Agreement. The Notice of Default claimed that the Company failed to maintain the “Required Reserve Amount” as required by the Third Baker Amendment. The Designated Agent, at the direction of the Baker Purchasers, accelerated repayment of the outstanding balance payable. As a result, approximately $ 92.7 100.0 On September 8, 2023, the Company entered into the Fourth Amendment to the Baker Bros. Purchase Agreement (the Fourth Baker Amendment) with the Baker Purchasers. The Fourth Amendment amends certain provisions within the Baker Bros. Purchase Agreement including: (i) the rescission of the Notice of Default delivered to the Company on March 7, 2023 and waiving the Events of Default named therein; (ii) the waiver of any and all other Events of Default existing as of the Fourth Amendment date; (iii) the removal of the conversion feature into shares of Company common stock, including the removal of any requirement to reserve shares of common stock for conversion of the Baker Notes as well as any registration rights related thereto; (iv) the clarification that for the sole purpose of enabling an ex-U.S. license agreement for such assets, any Patents, Trademarks or Copyrights acquired after the Effective Date shall be excluded from the definition of Collateral; and, (v) the removal of the requirement for the Company to obtain $ 100 The outstanding balance of the Baker Notes will continue to accrue interest at 10 The Company was required to make a $ 1.0 The cash payments will be determined based upon the quarterly global net revenue of Phexxi such that if the global net revenue is less than or equal to $5.0 million, the Company will pay 3% of such global net revenues; if the global net revenue is over $5.0 million and less than or equal to $7.0 million, the Company will continue to pay 3% on net revenue up to $5.0 million and 4% on the net revenue over $5.0 million; and if the global net revenue is over $7.0 million, the Company will pay 3% on the net revenue up to $5.0 million, 4% on the net revenue over $5.0 million up to $7.0 million, and 5% on net revenue over $7.0 million. The cash payments were payable beginning in the fourth quarter of 2023. Regardless of the percentage paid, the quarterly cash payment amounts, along with the $1.0 million upfront payment, will be deducted from the Repurchase Price as Applicable Reductions. The Fourth Amendment also granted the Company the ability to repurchase the principal amount and accrued and unpaid interest of the Baker Notes for up to a five-year period for the one-time Repurchase Price designated below: Schedule of Repurchase Price Reduction Date of Notes’ Repurchase Repurchase Price On or prior to September 8, 2024 $ 14,000,000 September 9, 2024-September 8, 2025 $ 16,750,000 September 9, 2025-September 8, 2026 $ 19,500,000 September 9, 2026-September 8, 2027 $ 22,250,000 September 9, 2027-September 8, 2028 $ 25,000,000 The Company evaluated whether any of the Embedded Features required bifurcation as a separate component. The Company elected the fair value option (FVO) under ASC 825, Financial Instruments Due to the execution of the Fourth Baker Amendment, the Company reviewed the Baker Notes in accordance with ASC 470, Debt . 15.6 73.2 12.5 75.3 73.2 Note 6 – Fair Value of Financial Instruments As part of the consideration for the Merger, on December 11, 2023, the Baker Purchasers signed an agreement to assign the Baker Notes to Aditxt (the December Assignment Agreement). Upon this December Assignment Agreement, Aditxt assumed all terms under the Baker Notes, with Aditxt becoming the new senior secured debtholder of the Company, governed by the requirements under the Fourth Baker Amendment. The Baker Notes were re-assigned back to the Baker Purchasers on February 26, 2024 (the February Assignment Agreement). Due to the execution of the February Assignment Agreement, the Company reviewed the Baker Notes in accordance with ASC 470. The Baker Notes, having been effectively terminated, were extinguished on February 26, 2024, resulting in removing the fair value of the old Baker Notes of $ 13.5 Note 6 – Fair Value of Financial Instruments As of March 31, 2024, the Baker Notes are recorded at fair value in the condensed consolidated balance sheet as short-term convertible notes payable with a total fair value of $ 12.3 102.0 Adjuvant Notes On October 14, 2020, the Company entered into a Securities Purchase Agreement (the Adjuvant Purchase Agreement) with Adjuvant Global Health Technology Fund, L.P., and Adjuvant Global Health Technology Fund DE, L.P. (together, the Adjuvant Purchasers), pursuant to which the Company sold unsecured convertible promissory notes (the Adjuvant Notes) in aggregate principal amount of $ 25.0 The Adjuvant Notes have a five-year 7.5 8.8 Interest expense for the Adjuvant Notes consist of the following, and is included in other expense, net on the condensed consolidated statements of operations for the three months ended March 31, 2024 and 2023 (in thousands): Schedule of Interest Expense 2024 2023 Three Months Ended March 31, 2024 2023 Coupon interest $ 536 $ 497 Amortization of issuance costs 28 68 Total $ 564 $ 565 The Adjuvant Notes are convertible, subject to customary 4.99 19.99 0.0001 6,843.75 6,843.75 18,750 100.0 On April 4, 2022, the Company entered into the first amendment to the Adjuvant Purchase Agreement (the Adjuvant Amendment). The Adjuvant Amendment extended the affirmative covenant to achieve $ 100.0 678.49 100 100 30 18,750 100.0 The Adjuvant Notes contain various customary affirmative and negative covenants agreed to by the Company. On September 12, 2022, the Company was in default of the Adjuvant Notes due to the default with the Baker Notes under the cross-default provision. On September 15, 2022, the Company entered into a Forbearance Agreement (the Adjuvant Forbearance Agreement) with the Adjuvant Purchasers, pursuant to which the Adjuvant Purchasers agreed to forbear from exercising any of their rights and remedies during the Forbearance Period as defined in therein, but solely with respect to the specified events of default provided under the Adjuvant Forbearance Agreement. On September 15, 2022, the Company also entered into the second amendment to the Adjuvant Purchase Agreement (the Second Adjuvant Amendment), pursuant to which the conversion price per share was reduced to $ 26.25 10 2.9 109,842 Note 8 - Stockholders’ Deficit 0.0158 0.0154 Note 10 – Subsequent Events The Adjuvant Notes are accounted for in accordance with authoritative guidance for convertible debt instruments and are classified as current liabilities in the condensed consolidated balance sheets. The aggregate proceeds of $ 25.0 million were initially classified as restricted cash for financial reporting purposes due to contractual stipulations that specify the types of expenses the money can be spent on and how it must be allocated. The conversion feature was required to be bifurcated as an embedded derivative because the Company did not have a sufficient number of shares reserved upon conversion as of March 31, 2023; however, the fair value of such feature was immaterial as of such date. As of June 30, 2023, the Company had a sufficient number of shares reserved and the conversion feature was reclassified to stockholders’ deficit in accordance with ASC 815, Derivatives and Hedging Note 6 - Fair Value of Financial Instruments The Company was in default of the Adjuvant Notes at September 30, 2023, due to the failure to meet the cumulative net sales requirement. However, Adjuvant forbore such default in October 2023 and therefore the Company is no longer in default. As of March 31, 2024, the Adjuvant Notes are recorded in the condensed consolidated balance sheet as short-term convertible notes payable with a total balance of $ 29.1 22.5 6.6 28.5 22.5 6.1 As of March 31, 2024, and assuming the current conversion price of $ 0.0158 1,842,275,987 Term Notes December 2022 and February, March, April, July, August, and September 2023 Notes (SSNs) The Company entered into eight similar Securities Purchase Agreements (SPAs) between December 2022 and September 2023 with certain investors. Each of the agreements were materially similar. The variable details of each SPA, such as the principal amount of each note offering, net proceeds, and maturity date, are outlined in the table below. Pursuant to each SPA, the Company agreed to sell in a registered direct offering (i) unsecured 8.0 0.0001 The SSNs interest rates are subject to increase to 12 % upon an event of default and the Notes have no Company right to prepayment prior to maturity; however, the Company has the option to redeem the respective SSNs at a redemption premium of 32.5 %. The Purchasers can also require the Company to redeem their notes at the respective premium rate tied to the occurrence of certain subsequent transactions, as well as require the Company to redeem the SSNs in the event of subsequent placements (as defined). Also, pursuant to the terms of the SPAs, Purchasers have certain rights to participate in subsequent issuances of the Company’s securities, subject to certain exceptions. Additionally, the conversion rate and warrant strike price are subject to adjustment upon the issuance of other securities (as defined) less than the stated conversion rate and strike price at issuance. The strike prices adjusted as discussed in the table below. Additionally, subsequent to March 31, 2024, the conversion price of the SSNs was adjusted to $ 0.0154 per share due to the price reset requirements in the SPA. The Company evaluated the SSNs in accordance with ASC 480 and determined that the Notes were all liability instruments at issuance. The applicable Notes were then evaluated in accordance with the requirements of ASC 825 and the Company concluded that they were not precluded from electing the fair value option for the applicable Notes. The Company also evaluated the Warrants in accordance with ASC 480 and determined that the Warrants issued before the Reverse Stock Split in May 2023 were required to be recorded as liabilities at fair value in the Company’s condensed consolidated balance sheets. The applicable SSNs were marked-to-market at each reporting date with changes in fair value recognized in the condensed consolidated statement of operations, unless the change is concluded to be related to changes in the Company’s credit rating, in which case the change was recognized as a component of accumulated other comprehensive income in the condensed consolidated balance sheets. As a result of the Reverse Stock Split, the Company had sufficient shares available for issuance to cover the potential exercises; therefore, the Warrants that were previously classified as liabilities were marked-to-market and reclassified to equity in May 2023. For the Warrants issued after the Reverse Stock Split, the Company determined they were required to be recorded in equity. On December 21, 2023, warrants to purchase up to 9,972,074 613 22,280 Note 10 – Subsequent Events Summary of SSNs and Warrants at Issuance (December 2022 to September 2023): Schedule of SSNs and Warrants Conversion Price Notes Principal At Issuance Net Proceeds Before Issuance costs Common Preferred Shares Maturity Date At Issuance At 3/31/2023 At 6/30/2023 At 9/30/2023 At 12/31/2023 At 3/31/2024 December 2022 Notes $ 2,308 $ 1,500 369,230 70 12/21/2025 $ 6.25 $ 1.625 $ 0.8125 $ 0.0845 $ 0.0615 $ 0.0158 February 2023 Notes (1) 1,385 900 653,538 - 2/17/2026 $ 2.50 $ 1.625 $ 0.8125 $ 0.0845 $ 0.0615 $ 0.0158 March 2023 Notes 600 390 240,000 - 3/17/2026 $ 2.50 $ 1.625 $ 0.8125 $ 0.0845 $ 0.0615 $ 0.0158 March 2023 Notes (2) 538 350 258,584 - 3/20/2026 $ 2.50 $ 1.625 $ 0.8125 $ 0.0845 $ 0.0615 $ 0.0158 April 2023 Notes 769 500 615,384 - 3/6/2026 $ 1.25 N/A $ 0.8125 $ 0.0845 $ 0.0615 $ 0.0158 July 2023 Notes 1,500 975 1,200,000 - 3/6/2026 $ 1.25 N/A N/A $ 0.0845 $ 0.0615 $ 0.0158 August 2023 Notes 1,000 650 799,999 - 8/4/2026 $ 1.25 N/A N/A $ 0.0845 $ 0.0615 $ 0.0158 September 2023 Notes (3) 2,885 1,875 26,997,041 - 9/26/2026 $ 0.13 N/A N/A $ 0.13 $ 0.0615 $ 0.0158 Total Offerings $ 10,985 $ 7,140 31,133,776 (1) Warrants include 99,692 (2) Warrants include 43,200 (3) Warrants include 22,189,349 0.13 4,807,692 0.001

Balance Sheet Details

Balance Sheet Details	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Details	5. Balance Sheet Details Inventories Inventories consist of the following (in thousands) for the period indicated: Schedule of Inventories March 31, 2024 December 31, 2023 Raw materials (1) $ 526 $ 520 Work in process - 386 Finished goods (1) 780 791 Total $ 1,306 $ 1,697 (1) The raw materials and finished goods balances included a combined estimated reserve on obsolescence and excess inventory which might not be sold prior to expiration of $ 0.2 0.3 1.3 Prepaid and Other Current Assets Prepaid and other current assets consist of the following (in thousands): Schedule of Prepaid and Other Current Assets March 31, 2024 December 31, 2023 Insurance $ 314 $ 777 Research & development 13 13 Other 295 405 Total $ 622 $ 1,195 Property and Equipment, Net Property and equipment, net, consists of the following (in thousands): Schedule of Property and Equipment Net Useful Life March 31, 2024 December 31, 2023 Research equipment 5 $ 586 $ 586 Computer equipment and software 3 151 647 Construction in-process - 1,152 1,156 Property and equipment gross 1,889 2,389 Less: accumulated depreciation (689 ) (1,186 ) Total, net $ 1,200 $ 1,203 Depreciation expense for property and equipment was immaterial and $ 0.2 Accrued Expenses Accrued expenses consist of the following (in thousands): Schedule of Accrued Expenses March 31, 2024 December 31, 2023 Clinical trial related costs $ 2,498 $ 2,498 Accrued royalty 1,336 1,146 Other 741 583 Total $ 4,575 $ 4,227

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair Value of Financial Liabilities The following tables summarize the Company’s convertible debt instruments as of March 31, 2024 and December 31, 2023, respectively (in thousands): Schedule of Fair Value of Financial Liabilities Fair Value As of March 31, 2024 Principal Amount Unamortized Issuance Costs Accrued Interest Net Carrying Amount Amount Leveling Baker Notes (1)(2) $ 101,974 $ - $ - $ 101,974 $ 12,260 Level 3 Adjuvant Notes (3) 22,500 - 6,601 29,101 N/A N/A December 2022 Notes (1) 959 - - 959 103 Level 3 February 2023 Notes (1) 924 - - 924 99 Level 3 March 2023 Notes (1) 1,189 - - 1,189 127 Level 3 April 2023 Notes (1) 832 - - 832 89 Level 3 July 2023 Notes (1) 1,335 - - 1,335 142 Level 3 August 2023 Notes (1) 1,054 - - 1,054 112 Level 3 September 2023 Notes (1) 3,004 - - 3,004 320 Level 3 Totals $ 133,771 $ - $ 6,601 $ 140,372 $ 13,252 N/A Fair Value As of December 31, 2023 Principal Amount Unamortized Issuance Costs Accrued Interest Net Carrying Amount Amount Leveling Baker Notes (1)(2) $ 99,460 $ - $ - $ 99,460 $ 13,510 Level 3 Adjuvant Notes (3) 22,500 (27 ) 6,064 28,537 N/A N/A December 2022 Notes (1) 940 - - 940 118 Level 3 February 2023 Notes (1) 905 - - 905 118 Level 3 March 2023 Notes (1) 1,204 - - 1,204 157 Level 3 April 2023 Notes (1) 816 - - 816 106 Level 3 July 2023 Notes (1) 1,534 - - 1,534 202 Level 3 August 2023 Notes (1) 1,033 - - 1,033 136 Level 3 September 2023 Notes (1) 2,945 - - 2,945 384 Level 3 Totals $ 131,337 $ (27 ) $ 6,064 $ 137,374 $ 14,731 N/A (1) These liabilities are/were carried at fair value in the condensed consolidated balance sheets. As such, the principal and accrued interest was included in the determination of fair value. The related debt issuance costs were expensed. (2) The Baker Notes principal amount includes $ 16.9 13.7 (3) The Adjuvant Notes are recorded in the condensed consolidated balance sheets at their net carrying amount which includes principal and accrued interest, net of unamortized issuance costs. The following tables summarize the Company’s derivative liabilities as of March 31, 2024 and December 31, 2024 as discussed in Note 8 – Stockholders’ Deficit Schedule of Fair Value of Financial Liabilities Fair Value March 31, 2024 December 31, 2023 Leveling Purchase rights $ 4,310 $ 1,926 Level 3 Total derivative liabilities $ 4,310 $ 1,926 Change in Fair Value of Level 3 Financial Liabilities The following table summarizes the changes in Level 3 financial liabilities related to Baker Notes and SSNs measured at fair value on a recurring basis for the three months ended March 31, 2024 (in thousands): Schedule of Change in Fair Value of Level 3 Financial Liabilities Baker Notes (Assigned to Aditxt; Reassigned Back to Baker; Note 4) Total SSNs (Note 4) Total Balance at December 31, 2023 $ 13,510 $ 1,221 $ 14,731 Extinguishment/conversion (13,510 ) (35 ) (13,545 ) Balance at issuance 12,390 - 12,390 Change in fair value presented in the Condensed Consolidated Statements of Comprehensive Operations (130 ) (194 ) (324 ) Balance at March 31, 2024 $ 12,260 $ 992 $ 13,252 The following table summarizes the changes in Level 3 financial liabilities related to Baker Notes and SSNs measured at fair value on a recurring basis for the three months ended March 31, 2023 (in thousands): Baker Notes Total SSNs (Note 4) Total Balance at December 31, 2022 $ 39,260 $ 156 $ 39,416 Balance at issuance - 12 12 Change in fair value presented in the Condensed Consolidated Statements of Operations - (161 ) (161 ) Change in fair value presented in the Condensed Consolidated Statements of Comprehensive Operations (15,460 ) - (15,460 ) Balance at March 31, 2023 $ 23,800 $ 7 $ 23,807 The following table summarizes the changes in Level 3 financial liabilities related to derivative liabilities measured at fair value on a recurring basis for the three months ended March 31, 2024 (in thousands): Purchase Rights Derivative Liabilities Total Balance at December 31, 2023 $ 1,926 $ 1,926 Balance at issuance 3,275 3,275 Exercises (89 ) (89 ) Change in fair value presented in the Condensed Consolidated Statements of Operations (802 ) (802 ) Balance at March 31, 2024 $ 4,310 $ 4,310 The following table summarizes the changes in Level 3 financial liabilities related to derivative liabilities measured at fair value on a recurring basis for the three months ended March 31, 2023 (in thousands): Derivative Liabilities Previously Classified as Equity Instruments May 2022 Public Offering Common Warrants June 2022 Baker Warrants December 2022 Warrants February and March 2023 Warrants Purchase Rights Derivative Liabilities Total Balance at December 31, 2022 $ 1 $ 303 $ 170 $ 107 $ - $ 1,095 $ 1,676 Balance at issuance - - - - 6 77 83 Exercises - (6 ) - - - (180 ) (186 ) Change in fair value presented in the Condensed Consolidated Statements of Operations (1 ) (291 ) (167 ) (106 ) - (886 ) (1,451 ) Balance at March 31, 2023 $ - $ 6 $ 3 $ 1 $ 6 $ 106 $ 122 Valuation Methodology From the third quarter of 2022 through the second quarter of 2023, the fair value of the Baker Notes issued as described in Note 4 – Debt Starting in the third quarter of 2023, the fair value of the Baker Notes, issued as described in Note 4 – Debt 5.0 15.0 The fair value of the Baker Notes is subject to uncertainty due to the assumptions that are used in the Monte Carlo simulation-based model. These factors include but are not limited to the Company’s future revenue, and the probability and timing of the exercise of the repurchase right. The fair value of the Baker Notes is sensitive to these estimated inputs made by management that are used in the calculation. SSNs The fair value of the SSNs issued as described in Note 4 – Debt 0.2 1.6 Purchase Rights The Adjuvant Purchase Rights and the May Note Purchase Rights (collectively Purchase Rights) are recorded as derivative liabilities in the condensed consolidated balance sheets. The Purchase Rights are valued using an OPM, like a Black-Scholes Methodology with changes in the fair value being recorded in the condensed consolidated statements of operations. The assumptions used in the OPM are considered level 3 assumptions and include, but are not limited to, the market value of invested capital, the cumulative equity value of the Company as a proxy for the exercise price and the expected term the Purchase Rights will be held prior to exercise and a risk-free interest rate. Warrants Warrants previously classified as liabilities were reclassified as equity instruments during the second quarter of 2023 as a result of the Reverse Stock Split. The Company will continue to re-evaluate the classification of its warrants at the close of each reporting period to determine their proper balance sheet classification. The warrants are valued using an OPM based on the applicable assumptions, which include the exercise price of the warrants, time to expiration, expected volatility of our peer group, risk-free interest rate, and expected dividends. The assumptions used in the OPM are considered level 3 assumptions and include, but are not limited to, the market value of invested capital, the cumulative equity value of the Company as a proxy for the exercise price, the expected term the warrants will be held prior to exercise, a risk-free interest rate and probability of change of control event. Additionally, as the warrants are re-priced under certain provisions in the agreements, at each re-pricing event, the Company must value the warrants using a Black-Scholes model immediately prior to and immediately following the re-pricing event. The incremental fair value is recorded as an increase to accumulated deficit and additional paid-in-capital, in accordance with ASC 470.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Operating Leases Fleet Lease In December 2019, the Company and Enterprise FM Trust (the Lessor) entered into a Master Equity Lease Agreement whereby the Company leases vehicles to be delivered by the Lessor from time to time with various monthly costs depending on whether the vehicles are delivered for a term of 24 36 20 0.3 Leases 12 24 2020 Lease and the First Amendment On October 3, 2019, the Company entered into an office lease for approximately 24,474 0.8 On April 14, 2020, the Company entered into the first amendment to the 2020 Lease for an additional 8,816 0.05 On March 20, 2023, the Company received a notice of default from its landlord for failing to timely pay March 2023 rent, resulting in a breach under the agreement. As a result, the Company’s letter of credit in the amount of $ 0.8 3.3 4.2 0.2 2022 Sublease On May 27, 2022, the Company entered into a sublease agreement with AMN Healthcare, Inc. (AMN), pursuant to which the Company agreed to sublease 16,637 rentable square feet of the High Bluff Premises to AMN for a term commencing on June 15, 2022 and ending coterminous with the 2020 Lease on September 30, 2025, in exchange for the sum of approximately $ 0.1 million per month, subject to an annual 3.5 % increase each year. Gross sublease income was zero for the three months ended March 31, 2024 and $ 0.3 million for the three months ended March 31, 2023. The sublease was terminated along with the settlement of the 2020 Lease in June 2023. Supplemental Financial Statement Information Schedule of Lease Cost Three Months Ended March 31, Lease Cost (in thousands) Classification 2024 2023 Operating lease expense Research and development $ 1 $ 66 Operating lease expense Selling and marketing 52 159 Operating lease expense General and administrative 3 231 Total $ 56 $ 456 Schedule of Lease Term and Discount Rate Lease Term and Discount Rate March 31, 2024 December 31, 2023 Weighted Average Remaining Lease Term (in years) 0.65 0.75 Weighted Average Discount Rate 12 % 12 % Schedule of Operating Lease Maturities Maturity of Operating Lease Liabilities (in thousands) March 31, 2024 Remainder of 2024 (9 months) $ 56 Year ending December 31, 2025 11 Total lease payments 67 Less imputed interest (8 ) Total $ 59 Schedule of Supplement Cash Outflows in Operating Leases Other information (in thousands) 2024 2023 Three Months Ended March 31, Other information (in thousands) 2024 2023 Cash paid for amounts included in the measurement of lease liabilities: Operating cash outflows in operating leases $ 64 $ 610 Other Contractual Commitments In November 2019, the Company entered into a supply and manufacturing agreement with a third-party to manufacture Phexxi, with potential to manufacture other product candidates, in accordance with all applicable current good manufacturing practice regulations. There were no Contingencies From time to time the Company may be involved in various lawsuits, legal proceedings, or claims that arise in the ordinary course of business. During the year ended December 31, 2023, the Company settled a portion of its trade payables with numerous vendors, which resulted in a $ 2.1 94 On December 14, 2020, a trademark dispute captioned TherapeuticsMD, Inc. v Evofem Biosciences, Inc., was filed in the U.S. District Court for the Southern District of Florida against the Company, alleging trademark infringement of certain trademarks owned by TherapeuticsMD under federal and state law (Case No. 9:20-cv-82296). On July 18, 2022, the Company settled the lawsuit with TherapeuticsMD, with certain requirements which may need to be performed by July 2024. Intellectual Property Rights In 2014, the Company entered into an amended and restated license agreement (the Rush License Agreement) with Rush University Medical Center (Rush University) pursuant to which Rush University granted the Company an exclusive, worldwide license of certain patents and know-how related to its multipurpose vaginal pH modulator technology. For the U.S. patent that the Company licensed from Rush University, multiple Orders Granting Interim Extension (OGIEs) have been received from the United States Patent and Trademark Office (USPTO), currently extending the expiration of this patent to March 2025. Pursuant to the Rush License Agreement, the Company is obligated to pay Rush University an earned royalty based upon a percentage of net sales in the range of mid-single digits until the expiration of this patent. In September 2020, the Company entered into the first amendment to the Rush License Agreement, pursuant to which the Company is also obligated to pay a minimum annual royalty amount of $ 0.1 0.1 0.2 1.3 1.1

Convertible and Redeemable Pref

Convertible and Redeemable Preferred Stock and Stockholders’ Deficit	3 Months Ended
	Mar. 31, 2024
Equity [Abstract]
Convertible and Redeemable Preferred Stock and Stockholders’ Deficit	Convertible and Redeemable Preferred Stock and Stockholders’ Deficit Warrants In April and June 2020, pursuant to the Baker Bros. Purchase Agreement, as discussed in Note 4 – Debt 2,732 4,575 0.0158 0.0154 Note 10 – Subsequent Events In May 2022, the Company completed an underwritten public offering (the May 2022 Public Offering) which included the issuance of common warrants to purchase 362,640 93.75 205,360 93.63 five-year 894,194 0.0158 In June 2022, as required by the Second Baker Amendment, the Company issued the June 2022 Baker Warrants to purchase up to 582,886 0.0001 93.75 five-year 4.99 19.99 0.0158 In February, March, April, July, August, and September 2023, pursuant to the SSNs as discussed in Note 4 – Debt 1,152,122 2.50 2,615,383 1.25 22,189,349 0.13 0.0158 On December 21, 2023, warrants to purchase up to 9,972,074 613 As of March 31, 2024, warrants to purchase up to 20,807,543 2.42 , Schedule of Warrants Type of Warrants Underlying common stock to be Purchased Exercise Price Issue Date Exercise Period Common Warrants 4 $ 6,918.75 June 11, 2014 June 11, 2014 to June 11, 2024 Common Warrants 451 $ 14,062.50 May 24, 2018 May 24, 2018 to May 24 2025 Common Warrants 888 $ 11,962.50 April 11, 2019 October 11, 2019 to April 11, 2026 Common Warrants 1,480 $ 11,962.50 June 10, 2019 December 10, 2019 to June 10, 2026 Common Warrants 1,639 $ 0.0158 April 24, 2020 April 24, 2020 to April 24, 2025 Common Warrants 1,092 $ 0.0158 June 9, 2020 June 9, 2020 to June 9, 2025 Common Warrants 8,003 $ 735.00 January 13, 2022 March 1, 2022 to March 1, 2027 Common Warrants 8,303 $ 897.56 March 1, 2022 March 1, 2022 to March 1, 2027 Common Warrants 6,666 $ 309.56 May 4, 2022 May 4, 2022 to May 4, 2027 Common Warrants 894,194 $ 0.0158 May 24, 2022 May 24, 2022 to May 24, 2027 Common Warrants 582,886 $ 0.0158 June 28, 2022 May 24, 2022 to June 28, 2027 Common Warrants 49,227 $ 0.0158 December 21, 2022 December 21, 2022 to December 21, 2027 Common Warrants 130,461 $ 0.0158 February 17, 2023 February 17, 2023 to February 17, 2028 Common Warrants 258,584 $ 0.0158 March 20, 2023 March 20, 2023 to March 20, 2028 Common Warrants 369,231 $ 0.0158 April 5, 2023 April 5, 2023 to April 5, 2028 Common Warrants 349,463 $ 0.0158 July 3, 2023 July 3, 2023 to July 3, 2028 Common Warrants 615,384 $ 0.0158 August 4, 2023 August 4, 2023 to August 4, 2028 Common Warrants 12,721,893 $ 0.0158 September 27, 2023 September 27, 2023 to September 27, 2028 Prefunded Common Warrants 4,807,694 $ 0.0010 September 27, 2023 September 27, 2023 to September 27, 2028 Total 20,807,543 Preferred Stock Effective December 15, 2021, the Company amended and restated its certificate of incorporation, under which the Company is currently authorized to issue up to 5,000,000 0.0001 Convertible and Redeemable Preferred Stock On August 7, 2023, the Company filed a Certificate of Designation of Series E-1 Convertible Preferred Stock (E-1 Certificate of Designation), par value $ 0.0001 2,300 0.40 25 On August 7, 2023, certain investors party to the December 2022 Notes and the February 2023 Notes exchanged $ 1.8 1,800 0.0158 1.8 On December 11, 2023, the Company filed a Certificate of Designation of Series F-1 Convertible Preferred Stock (F-1 Certificate of Designation), par value $ 0.0001 95,000 0.0635 On December 21, 2023, the Company issued a total of 22,280 613 9,972,074 21,667 22,280 Note 10 – Subsequent Events Nonconvertible and Redeemable Preferred Stock On December 16, 2022, the Company filed a Certificate of Designation of Series D Non-Convertible Preferred Stock (the D Certificate of Designation), par value $ 0.0001 70 1 70 Note 4 – Debt Common Stock Effective September 14, 2023, the Company further amended its amended and restated certificate of incorporation to increase the number of authorized shares of common stock to 3,000,000,000 Purchase Rights On September 15, 2022, the Company entered into certain exchange agreements with the Adjuvant Purchasers and the May 2022 Notes Purchasers to exchange, upon request, the Purchase Rights for an aggregate of 942,080 Note 6 – Fair Value of Financial Instruments 24.7 21,667 In connection with the SSNs issuances, during the three months ended March 31, 2024 and 2023, the Company increased the number of outstanding Purchase Rights by 1,145,333,158 10,467,332 3.3 0.1 The Company issued 17,725,000 shares of common stock upon the exercise of certain Purchase Rights during the three months ended March 31, 2024. As of March 31, 2024, Purchase Rights of 1,530,645,242 shares of the Company’s common stock remained outstanding. Common Stock Reserved for Future Issuance Common stock reserved for future issuance is as follows in common equivalent shares as of March 31, 2024: Summary of Common Stock Reserved for Future Issuance Common stock issuable upon the exercise of stock options outstanding 3,747 Common stock issuable upon the exercise of common stock warrants 10,598,205 Common stock available for future issuance under the 2019 ESPP 509 Common stock available for future issuance under the Amended and Restated 2014 Plan 5,789 Common stock available for future issuance under the Amended Inducement Plan 609 Common stock reserved for the exercise of purchase rights 722,646,377 Common stock reserved for the conversion of convertible notes 148,541,458 Common stock reserved for the conversion of series E-1 preferred stock 33,750,860 Total common stock reserved for future issuance (1) 915,547,554 (1) The potentially dilutive securities in Note 2 – Summary of Significant Accounting Policies includes all potentially dilutive securities that are not included in the diluted EPS as per U.S. GAAP, whereas the total common stock reserved for future issuance in the table above includes the shares that must legally be reserved based on the applicable instruments’ agreements.

Stock-based Compensation

Stock-based Compensation	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Stock-based Compensation	Stock-based Compensation Equity Incentive Plans The following table summarizes stock-based compensation expense related to stock options granted to employees, non-employee directors and consultants included in the condensed consolidated statements of operations as follows (in thousands): Schedule of Stock-based Compensation Expense Related to Stock Options 2024 2023 Three Months Ended March 31, 2024 2023 Research and development $ 16 $ 40 Selling and marketing 35 57 General and administrative 186 320 Total $ 237 $ 417 Stock Options There were no 0.9 1.4 Employee Stock Purchase Plan The purchase price under the 2019 ESPP is 85 % of the lesser of the fair market value of the common stock on the first or the last business day of an offering period. The maximum number of shares of common stock that may be purchased by any participant during an offering period is equal to $ 25,000 divided by the fair market value of the common stock on the first business day of an offering period. In October 2022, the Board suspended future offering periods. Restricted Stock Awards There were no shares of performance-based RSAs granted in 2023 to the Company’s executive management team. For performance-based RSAs, (i) the fair value of the award is determined on the grant date; (ii) the Company assesses the probability of achieving each individual milestone associated with the award using reasonable assumptions based on the Company’s operation performance towards each milestone; (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met; and (iv) the Company reassesses the probability of achieving each individual milestone at each reporting date, and any change in estimate is accounted for through a cumulative adjustment in the period when the change in estimate occurs. Non-performance based RSAs are valued at the fair value on the grant date and the associated expenses will be recognized over the vesting period. As of March 31, 2024, there was no

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2024
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Termination and Reinstatement of Merger Agreement On April 26, 2024, the Company delivered a termination notice to Aditxt notifying it that the Company was exercising its right to terminate the Merger Agreement effective April 26, 2024 (the Termination Notice), in accordance with Section 8.1(f) of the Merger Agreement, as revised in the third amendment to the Merger Agreement, made on February 29, 2024. Reinstatement and Amendment of Merger Agreement On May 2, 2024, the Company, the Merger Sub and Aditxt entered into the Reinstatement and Fourth Amendment to the Merger Agreement (the “Fourth Amendment”) in order to waive and amend, among other things, several provisions. This Fourth Amendment reinstates the Merger Agreement, as amended by the Fourth Amendment, as if never terminated. In consideration of the Fourth Amendment, Aditxt agreed to pay the Company $ 1.0 0.0001 1,000 2.5 2,500 1.5 1.0 Conversion Price Reset At the close of market on April 19, 2024, the conversion price for certain outstanding financial instruments (as described in Note 4 – Debt Note 8 – Stockholders’ Deficit 0.0154 Warrants and Purchase Rights Exercises and Notes Conversions Subsequent to March 31, 2024, the Company 6,150,000 Purchase Rights were exercised in a cashless transaction for an equivalent number of shares of common stock. There were also cashless conversions whereby $ 0.1 7,200,000

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the notes thereto. Significant estimates affecting amounts reported or disclosed in the condensed consolidated financial statements include, but are not limited to: the assumptions used in measuring the revenue gross-to-net variable consideration items; the trade accounts receivable credit loss reserve estimate; the assumptions used in estimating the fair value of convertible notes, preferred stock, warrants and purchase rights issued; the assumptions used in the valuation of inventory; the useful lives of property and equipment; the recoverability of long-lived assets; and the valuation of deferred tax assets. These assumptions are more fully described in Note 3 – Revenue Note 4 – Debt Note 6 - Fair Value of Financial Instruments Note 7 - Commitments and Contingencies Note 9 - Stock-based Compensation
Segment Reporting	Segment Reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker, the Chief Executive Officer of the Company, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment.
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. Deposits in the Company’s checking, time deposit and investment accounts are maintained in federally insured financial institutions and are subject to federally insured limits or limits set by Securities Investor Protection Corporation. The Company invests in funds through a major U.S. bank and is exposed to credit risk in the event of default to the extent of amounts recorded on the condensed consolidated balance sheets. The Company has not experienced any losses in such accounts and believes it is not exposed to significant concentrations of credit risk on its cash, cash equivalents and restricted cash balances on amounts in excess of federally insured limits due to the financial position of the depository institutions in which these deposits are held. The Company is also subject to credit risk related to its trade accounts receivable from product sales. Its customers are located in the U.S. and consist of wholesale distributors, retail pharmacies, and mail-order specialty pharmacies. The Company extends credit to its customers in the normal course of business after evaluating their overall financial condition and evaluates the collectability of its accounts receivable by periodically reviewing the age of the receivables, the financial condition of its customers, and its past collection experience. Historically, the Company has not experienced any credit losses. As of March 31, 2024, based on the evaluation of these factors the Company did not record an allowance for doubtful accounts. Phexxi is distributed primarily through three major distributors and mail-order pharmacies, who receive service fees calculated as a percentage of the gross sales, and a fee-per-unit shipped, respectively. These entities are not obligated to purchase any set number of units. They distribute Phexxi on demand as orders are received. For the three months ended March 31, 2024, and 2023, the Company’s three largest customers combined made up approximately 82 % and 86 % of its gross product sales, respectively. As of March 31, 2024 and December 31, 2023, the Company’s three largest customers combined made up 89 % and 87 %, respectively, of its trade accounts receivable balance.
Significant Accounting Policies	Significant Accounting Policies There have been no changes to the significant accounting policies that were described in Note 2 – Summary of Significant Accounting Policies of the 2023 Audited Financial Statements in the Company’s Annual Report.
Cash, Cash Equivalents and Restricted Cash	Cash, Cash Equivalents and Restricted Cash Cash and cash equivalents consist of readily available cash in checking accounts and money market funds. Restricted cash consists of cash held in monthly time deposit accounts and letters of credit as described in Note 7- Commitments and Contingencies 0.3 25.0 0.8 The following table provides a reconciliation of cash, cash equivalents and restricted cash, reported within the condensed consolidated statements of cash flows (in thousands): Schedule of Reconciliation of Cash and Restricted Cash 2024 2023 Three months ended March 31, 2024 2023 Cash and cash equivalents $ - $ 639 Restricted cash 689 895 Total cash, cash equivalents and restricted cash presented in the condensed consolidated statements of cash flows $ 689 $ 1,534
Net Loss Per Share	Net Loss Per Share Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. The net loss available to common stockholders is adjusted for amounts in accumulated deficit related to the deemed dividends triggered for certain financial instruments. Such adjustment was immaterial and zero in the three months ended March 31, 2024 and 2023, respectively. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, potentially dilutive securities are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for the three months ended March 31, 2024 and 2023. Potentially dilutive securities excluded from the calculation of diluted net loss per share are summarized in the table below. Common shares were calculated for the convertible preferred stock and the convertible debt using the if-converted method. Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share 2024 2023 Three months ended March 31, 2024 2023 Options to purchase common stock 3,747 4,843 Warrants to purchase common stock 20,807,543 3,180,282 Purchase rights to purchase common stock 1,530,645,242 14,238,827 Convertible debt 2,430,230,049 18,042,988 Series E-1 and F-1 preferred stock 1,531,629,677 - Total (1) 5,513,316,258 35,466,940 (1) The potentially dilutive securities in the table above include all potentially dilutive securities that are not included in the diluted EPS as per U.S. GAAP, whereas the total common stock reserved for future issuance in Note 8 – Stockholders’ Deficit
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements No significant new standards have been adopted during the three months ended March 31, 2024.
Recently Issued Accounting Pronouncements — Not Yet Adopted	Recently Issued Accounting Pronouncements — Not Yet Adopted From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standards setting bodies that are adopted as of the specified effective date. In November 2023, the FASB issued ASU No. 2023-07, Improvements to Reportable Segment Disclosures In December 2023, the FASB issued ASU No. 2023-09, Income Taxes: Improvements to Income Tax Disclosures The Company does not believe the impact of any other recently issued standards and any issued but not yet effective standards will have a material impact on its condensed consolidated financial statements upon adoption.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Schedule of Reconciliation of Cash and Restricted Cash	The following table provides a reconciliation of cash, cash equivalents and restricted cash, reported within the condensed consolidated statements of cash flows (in thousands): Schedule of Reconciliation of Cash and Restricted Cash 2024 2023 Three months ended March 31, 2024 2023 Cash and cash equivalents $ - $ 639 Restricted cash 689 895 Total cash, cash equivalents and restricted cash presented in the condensed consolidated statements of cash flows $ 689 $ 1,534
Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share	Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share 2024 2023 Three months ended March 31, 2024 2023 Options to purchase common stock 3,747 4,843 Warrants to purchase common stock 20,807,543 3,180,282 Purchase rights to purchase common stock 1,530,645,242 14,238,827 Convertible debt 2,430,230,049 18,042,988 Series E-1 and F-1 preferred stock 1,531,629,677 - Total (1) 5,513,316,258 35,466,940 (1) The potentially dilutive securities in the table above include all potentially dilutive securities that are not included in the diluted EPS as per U.S. GAAP, whereas the total common stock reserved for future issuance in Note 8 – Stockholders’ Deficit

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
Schedule of Repurchase Price Reduction	The Fourth Amendment also granted the Company the ability to repurchase the principal amount and accrued and unpaid interest of the Baker Notes for up to a five-year period for the one-time Repurchase Price designated below: Schedule of Repurchase Price Reduction Date of Notes’ Repurchase Repurchase Price On or prior to September 8, 2024 $ 14,000,000 September 9, 2024-September 8, 2025 $ 16,750,000 September 9, 2025-September 8, 2026 $ 19,500,000 September 9, 2026-September 8, 2027 $ 22,250,000 September 9, 2027-September 8, 2028 $ 25,000,000
Schedule of Interest Expense	Interest expense for the Adjuvant Notes consist of the following, and is included in other expense, net on the condensed consolidated statements of operations for the three months ended March 31, 2024 and 2023 (in thousands): Schedule of Interest Expense 2024 2023 Three Months Ended March 31, 2024 2023 Coupon interest $ 536 $ 497 Amortization of issuance costs 28 68 Total $ 564 $ 565
Schedule of SSNs and Warrants	Summary of SSNs and Warrants at Issuance (December 2022 to September 2023): Schedule of SSNs and Warrants Conversion Price Notes Principal At Issuance Net Proceeds Before Issuance costs Common Preferred Shares Maturity Date At Issuance At 3/31/2023 At 6/30/2023 At 9/30/2023 At 12/31/2023 At 3/31/2024 December 2022 Notes $ 2,308 $ 1,500 369,230 70 12/21/2025 $ 6.25 $ 1.625 $ 0.8125 $ 0.0845 $ 0.0615 $ 0.0158 February 2023 Notes (1) 1,385 900 653,538 - 2/17/2026 $ 2.50 $ 1.625 $ 0.8125 $ 0.0845 $ 0.0615 $ 0.0158 March 2023 Notes 600 390 240,000 - 3/17/2026 $ 2.50 $ 1.625 $ 0.8125 $ 0.0845 $ 0.0615 $ 0.0158 March 2023 Notes (2) 538 350 258,584 - 3/20/2026 $ 2.50 $ 1.625 $ 0.8125 $ 0.0845 $ 0.0615 $ 0.0158 April 2023 Notes 769 500 615,384 - 3/6/2026 $ 1.25 N/A $ 0.8125 $ 0.0845 $ 0.0615 $ 0.0158 July 2023 Notes 1,500 975 1,200,000 - 3/6/2026 $ 1.25 N/A N/A $ 0.0845 $ 0.0615 $ 0.0158 August 2023 Notes 1,000 650 799,999 - 8/4/2026 $ 1.25 N/A N/A $ 0.0845 $ 0.0615 $ 0.0158 September 2023 Notes (3) 2,885 1,875 26,997,041 - 9/26/2026 $ 0.13 N/A N/A $ 0.13 $ 0.0615 $ 0.0158 Total Offerings $ 10,985 $ 7,140 31,133,776 (1) Warrants include 99,692 (2) Warrants include 43,200 (3) Warrants include 22,189,349 0.13 4,807,692 0.001

Balance Sheet Details (Tables)

Balance Sheet Details (Tables)	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Inventories	Inventories consist of the following (in thousands) for the period indicated: Schedule of Inventories March 31, 2024 December 31, 2023 Raw materials (1) $ 526 $ 520 Work in process - 386 Finished goods (1) 780 791 Total $ 1,306 $ 1,697 (1) The raw materials and finished goods balances included a combined estimated reserve on obsolescence and excess inventory which might not be sold prior to expiration of $ 0.2 0.3 1.3
Schedule of Prepaid and Other Current Assets	Prepaid and other current assets consist of the following (in thousands): Schedule of Prepaid and Other Current Assets March 31, 2024 December 31, 2023 Insurance $ 314 $ 777 Research & development 13 13 Other 295 405 Total $ 622 $ 1,195
Schedule of Property and Equipment Net	Property and equipment, net, consists of the following (in thousands): Schedule of Property and Equipment Net Useful Life March 31, 2024 December 31, 2023 Research equipment 5 $ 586 $ 586 Computer equipment and software 3 151 647 Construction in-process - 1,152 1,156 Property and equipment gross 1,889 2,389 Less: accumulated depreciation (689 ) (1,186 ) Total, net $ 1,200 $ 1,203
Schedule of Accrued Expenses	Accrued expenses consist of the following (in thousands): Schedule of Accrued Expenses March 31, 2024 December 31, 2023 Clinical trial related costs $ 2,498 $ 2,498 Accrued royalty 1,336 1,146 Other 741 583 Total $ 4,575 $ 4,227

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2024
Short-Term Debt [Line Items]
Schedule of Fair Value of Financial Liabilities	The following tables summarize the Company’s derivative liabilities as of March 31, 2024 and December 31, 2024 as discussed in Note 8 – Stockholders’ Deficit Schedule of Fair Value of Financial Liabilities Fair Value March 31, 2024 December 31, 2023 Leveling Purchase rights $ 4,310 $ 1,926 Level 3 Total derivative liabilities $ 4,310 $ 1,926
Schedule of Change in Fair Value of Level 3 Financial Liabilities	The following table summarizes the changes in Level 3 financial liabilities related to Baker Notes and SSNs measured at fair value on a recurring basis for the three months ended March 31, 2024 (in thousands): Schedule of Change in Fair Value of Level 3 Financial Liabilities Baker Notes (Assigned to Aditxt; Reassigned Back to Baker; Note 4) Total SSNs (Note 4) Total Balance at December 31, 2023 $ 13,510 $ 1,221 $ 14,731 Extinguishment/conversion (13,510 ) (35 ) (13,545 ) Balance at issuance 12,390 - 12,390 Change in fair value presented in the Condensed Consolidated Statements of Comprehensive Operations (130 ) (194 ) (324 ) Balance at March 31, 2024 $ 12,260 $ 992 $ 13,252 The following table summarizes the changes in Level 3 financial liabilities related to Baker Notes and SSNs measured at fair value on a recurring basis for the three months ended March 31, 2023 (in thousands): Baker Notes Total SSNs (Note 4) Total Balance at December 31, 2022 $ 39,260 $ 156 $ 39,416 Balance at issuance - 12 12 Change in fair value presented in the Condensed Consolidated Statements of Operations - (161 ) (161 ) Change in fair value presented in the Condensed Consolidated Statements of Comprehensive Operations (15,460 ) - (15,460 ) Balance at March 31, 2023 $ 23,800 $ 7 $ 23,807 The following table summarizes the changes in Level 3 financial liabilities related to derivative liabilities measured at fair value on a recurring basis for the three months ended March 31, 2024 (in thousands): Purchase Rights Derivative Liabilities Total Balance at December 31, 2023 $ 1,926 $ 1,926 Balance at issuance 3,275 3,275 Exercises (89 ) (89 ) Change in fair value presented in the Condensed Consolidated Statements of Operations (802 ) (802 ) Balance at March 31, 2024 $ 4,310 $ 4,310 The following table summarizes the changes in Level 3 financial liabilities related to derivative liabilities measured at fair value on a recurring basis for the three months ended March 31, 2023 (in thousands): Derivative Liabilities Previously Classified as Equity Instruments May 2022 Public Offering Common Warrants June 2022 Baker Warrants December 2022 Warrants February and March 2023 Warrants Purchase Rights Derivative Liabilities Total Balance at December 31, 2022 $ 1 $ 303 $ 170 $ 107 $ - $ 1,095 $ 1,676 Balance at issuance - - - - 6 77 83 Exercises - (6 ) - - - (180 ) (186 ) Change in fair value presented in the Condensed Consolidated Statements of Operations (1 ) (291 ) (167 ) (106 ) - (886 ) (1,451 ) Balance at March 31, 2023 $ - $ 6 $ 3 $ 1 $ 6 $ 106 $ 122
Convertible Debt [Member]
Short-Term Debt [Line Items]
Schedule of Fair Value of Financial Liabilities	The following tables summarize the Company’s convertible debt instruments as of March 31, 2024 and December 31, 2023, respectively (in thousands): Schedule of Fair Value of Financial Liabilities Fair Value As of March 31, 2024 Principal Amount Unamortized Issuance Costs Accrued Interest Net Carrying Amount Amount Leveling Baker Notes (1)(2) $ 101,974 $ - $ - $ 101,974 $ 12,260 Level 3 Adjuvant Notes (3) 22,500 - 6,601 29,101 N/A N/A December 2022 Notes (1) 959 - - 959 103 Level 3 February 2023 Notes (1) 924 - - 924 99 Level 3 March 2023 Notes (1) 1,189 - - 1,189 127 Level 3 April 2023 Notes (1) 832 - - 832 89 Level 3 July 2023 Notes (1) 1,335 - - 1,335 142 Level 3 August 2023 Notes (1) 1,054 - - 1,054 112 Level 3 September 2023 Notes (1) 3,004 - - 3,004 320 Level 3 Totals $ 133,771 $ - $ 6,601 $ 140,372 $ 13,252 N/A Fair Value As of December 31, 2023 Principal Amount Unamortized Issuance Costs Accrued Interest Net Carrying Amount Amount Leveling Baker Notes (1)(2) $ 99,460 $ - $ - $ 99,460 $ 13,510 Level 3 Adjuvant Notes (3) 22,500 (27 ) 6,064 28,537 N/A N/A December 2022 Notes (1) 940 - - 940 118 Level 3 February 2023 Notes (1) 905 - - 905 118 Level 3 March 2023 Notes (1) 1,204 - - 1,204 157 Level 3 April 2023 Notes (1) 816 - - 816 106 Level 3 July 2023 Notes (1) 1,534 - - 1,534 202 Level 3 August 2023 Notes (1) 1,033 - - 1,033 136 Level 3 September 2023 Notes (1) 2,945 - - 2,945 384 Level 3 Totals $ 131,337 $ (27 ) $ 6,064 $ 137,374 $ 14,731 N/A (1) These liabilities are/were carried at fair value in the condensed consolidated balance sheets. As such, the principal and accrued interest was included in the determination of fair value. The related debt issuance costs were expensed. (2) The Baker Notes principal amount includes $ 16.9 13.7 (3) The Adjuvant Notes are recorded in the condensed consolidated balance sheets at their net carrying amount which includes principal and accrued interest, net of unamortized issuance costs. The following tables summarize the Company’s derivative liabilities as of March 31, 2024 and December 31, 2024 as discussed in Note 8 – Stockholders’ Deficit Schedule of Fair Value of Financial Liabilities Fair Value March 31, 2024 December 31, 2023 Leveling Purchase rights $ 4,310 $ 1,926 Level 3 Total derivative liabilities $ 4,310 $ 1,926

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Schedule of Lease Cost	Schedule of Lease Cost Three Months Ended March 31, Lease Cost (in thousands) Classification 2024 2023 Operating lease expense Research and development $ 1 $ 66 Operating lease expense Selling and marketing 52 159 Operating lease expense General and administrative 3 231 Total $ 56 $ 456
Schedule of Lease Term and Discount Rate	Schedule of Lease Term and Discount Rate Lease Term and Discount Rate March 31, 2024 December 31, 2023 Weighted Average Remaining Lease Term (in years) 0.65 0.75 Weighted Average Discount Rate 12 % 12 %
Schedule of Operating Lease Maturities	Schedule of Operating Lease Maturities Maturity of Operating Lease Liabilities (in thousands) March 31, 2024 Remainder of 2024 (9 months) $ 56 Year ending December 31, 2025 11 Total lease payments 67 Less imputed interest (8 ) Total $ 59
Schedule of Supplement Cash Outflows in Operating Leases	Schedule of Supplement Cash Outflows in Operating Leases Other information (in thousands) 2024 2023 Three Months Ended March 31, Other information (in thousands) 2024 2023 Cash paid for amounts included in the measurement of lease liabilities: Operating cash outflows in operating leases $ 64 $ 610

Convertible and Redeemable Pr_2

Convertible and Redeemable Preferred Stock and Stockholders’ Deficit (Tables)	3 Months Ended
	Mar. 31, 2024
Equity [Abstract]
Schedule of Warrants	Schedule of Warrants Type of Warrants Underlying common stock to be Purchased Exercise Price Issue Date Exercise Period Common Warrants 4 $ 6,918.75 June 11, 2014 June 11, 2014 to June 11, 2024 Common Warrants 451 $ 14,062.50 May 24, 2018 May 24, 2018 to May 24 2025 Common Warrants 888 $ 11,962.50 April 11, 2019 October 11, 2019 to April 11, 2026 Common Warrants 1,480 $ 11,962.50 June 10, 2019 December 10, 2019 to June 10, 2026 Common Warrants 1,639 $ 0.0158 April 24, 2020 April 24, 2020 to April 24, 2025 Common Warrants 1,092 $ 0.0158 June 9, 2020 June 9, 2020 to June 9, 2025 Common Warrants 8,003 $ 735.00 January 13, 2022 March 1, 2022 to March 1, 2027 Common Warrants 8,303 $ 897.56 March 1, 2022 March 1, 2022 to March 1, 2027 Common Warrants 6,666 $ 309.56 May 4, 2022 May 4, 2022 to May 4, 2027 Common Warrants 894,194 $ 0.0158 May 24, 2022 May 24, 2022 to May 24, 2027 Common Warrants 582,886 $ 0.0158 June 28, 2022 May 24, 2022 to June 28, 2027 Common Warrants 49,227 $ 0.0158 December 21, 2022 December 21, 2022 to December 21, 2027 Common Warrants 130,461 $ 0.0158 February 17, 2023 February 17, 2023 to February 17, 2028 Common Warrants 258,584 $ 0.0158 March 20, 2023 March 20, 2023 to March 20, 2028 Common Warrants 369,231 $ 0.0158 April 5, 2023 April 5, 2023 to April 5, 2028 Common Warrants 349,463 $ 0.0158 July 3, 2023 July 3, 2023 to July 3, 2028 Common Warrants 615,384 $ 0.0158 August 4, 2023 August 4, 2023 to August 4, 2028 Common Warrants 12,721,893 $ 0.0158 September 27, 2023 September 27, 2023 to September 27, 2028 Prefunded Common Warrants 4,807,694 $ 0.0010 September 27, 2023 September 27, 2023 to September 27, 2028 Total 20,807,543
Summary of Common Stock Reserved for Future Issuance	Common stock reserved for future issuance is as follows in common equivalent shares as of March 31, 2024: Summary of Common Stock Reserved for Future Issuance Common stock issuable upon the exercise of stock options outstanding 3,747 Common stock issuable upon the exercise of common stock warrants 10,598,205 Common stock available for future issuance under the 2019 ESPP 509 Common stock available for future issuance under the Amended and Restated 2014 Plan 5,789 Common stock available for future issuance under the Amended Inducement Plan 609 Common stock reserved for the exercise of purchase rights 722,646,377 Common stock reserved for the conversion of convertible notes 148,541,458 Common stock reserved for the conversion of series E-1 preferred stock 33,750,860 Total common stock reserved for future issuance (1) 915,547,554 (1) The potentially dilutive securities in Note 2 – Summary of Significant Accounting Policies includes all potentially dilutive securities that are not included in the diluted EPS as per U.S. GAAP, whereas the total common stock reserved for future issuance in the table above includes the shares that must legally be reserved based on the applicable instruments’ agreements.

Stock-based Compensation (Table

Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Stock-based Compensation Expense Related to Stock Options	The following table summarizes stock-based compensation expense related to stock options granted to employees, non-employee directors and consultants included in the condensed consolidated statements of operations as follows (in thousands): Schedule of Stock-based Compensation Expense Related to Stock Options 2024 2023 Three Months Ended March 31, 2024 2023 Research and development $ 16 $ 40 Selling and marketing 35 57 General and administrative 186 320 Total $ 237 $ 417

Description of Business and B_2

Description of Business and Basis of Presentation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022	May 10, 2024	Oct. 03, 2022
Product Information [Line Items]
Revenue from product sales	$ 3,603	$ 5,809
Working capital deficit	67,300
Accumulated deficit	$ 893,555		$ 888,699
Share price						$ 0.01
Subsequent Event [Member]
Product Information [Line Items]
Share price					$ 0.0136
Phexxi [Member]
Product Information [Line Items]
Revenue from product sales			$ 18,200	$ 16,800

Schedule of Reconciliation of C

Schedule of Reconciliation of Cash and Restricted Cash (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Cash and cash equivalents			$ 639
Restricted cash	689	580	895
Total cash, cash equivalents and restricted cash presented in the condensed consolidated statements of cash flows	$ 689	$ 580	$ 1,534	$ 4,776

Schedule of Potentially Dilutiv

Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares		3 Months Ended
		Mar. 31, 2024	Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	[1]	5,513,316,258	35,466,940
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total		3,747	4,843
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total		20,807,543	3,180,282
Rights [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total		1,530,645,242	14,238,827
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total		2,430,230,049	18,042,988
Series E One And F One Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total		1,531,629,677
[1]The potentially dilutive securities in the table above include all potentially dilutive securities that are not included in the diluted EPS as per U.S. GAAP, whereas the total common stock reserved for future issuance in Note 8 – Stockholders’ Deficit

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Product Information [Line Items]
Proceeds from issuancde of notes		$ 25
Warrant, Down Round Feature, Decrease in Net Income to Common Shareholder, Amount		0
Building and Building Improvements [Member]
Product Information [Line Items]
Letters of credit		0.3
Building and Building Improvements [Member] | Letter of Credit [Member]
Product Information [Line Items]
Letter of credit, breach of contract		$ 0.8
Revenue Benchmark [Member] | Three Largest Customers Combined [Member] | Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration Risk, Percentage	82%	86%
Accounts Receivable [Member] | Four Largest Customers Combined [Member] | Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration Risk, Percentage	89%		87%

Revenue (Details Narrative)

Revenue (Details Narrative) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Trade accounts receivable	$ 0.2	$ 0.3
Other liabilities, current	$ 3.2	$ 3.2
Minimum [Member]
Payment term	31 days
Maximum [Member]
Payment term	66 days

Schedule of Repurchase Price Re

Schedule of Repurchase Price Reduction (Details) - Baker Notes [Member] $ in Thousands	Sep. 08, 2023 USD ($)
Prior To September 8, 2024 [Member]
Debt Instrument [Line Items]
Debt instrument, repurchase amount	$ 14,000,000
September 9, 2024 - September 8, 2025 [Member]
Debt Instrument [Line Items]
Debt instrument, repurchase amount	16,750,000
September 9, 2025 - September 8, 2026 [Member]
Debt Instrument [Line Items]
Debt instrument, repurchase amount	19,500,000
September 9, 2026 - September 8, 2027 [Member]
Debt Instrument [Line Items]
Debt instrument, repurchase amount	22,250,000
September 9, 2027 - September 8, 2028 [Member]
Debt Instrument [Line Items]
Debt instrument, repurchase amount	$ 25,000,000

Schedule of Interest Expense (D

Schedule of Interest Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Debt Disclosure [Abstract]
Coupon interest	$ 536	$ 497
Amortization of issuance costs	28	68
Total	$ 564	$ 565

Schedule of SSNs and Warrants (

Schedule of SSNs and Warrants (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended
		Mar. 31, 2024		Dec. 31, 2023		Sep. 30, 2023	Jun. 30, 2023		Mar. 31, 2023		Sep. 30, 2022
Short-Term Debt [Line Items]
Preferred Shares		0		0
December 2022 Notes [Member]
Short-Term Debt [Line Items]
Principal at issuance		$ 2,308
Gross proceeds before issuance costs		$ 1,500
Warrants at issued (common stock)		369,230
Preferred Shares		70
Maturity Date		Dec. 21, 2025
Conversion price		$ 0.0158		$ 0.0615		$ 0.0845	$ 0.8125		$ 1.625		$ 6.25
February 2023 Notes [Member]
Short-Term Debt [Line Items]
Principal at issuance	[1]	$ 1,385
Gross proceeds before issuance costs	[1]	$ 900
Warrants at issued (common stock)	[1]	653,538,000
Maturity Date	[1]	Feb. 17, 2026
Conversion price	[1]	$ 0.0158		0.0615		0.0845	0.8125		1.625		2.50
March 2023 Notes [Member]
Short-Term Debt [Line Items]
Principal at issuance		$ 600
Gross proceeds before issuance costs		$ 390
Warrants at issued (common stock)		240,000
Maturity Date		Mar. 17, 2026
Conversion price		$ 0.0158		0.0615		0.0845	0.8125		1.625		2.50
March Two 2023 Notes [Member]
Short-Term Debt [Line Items]
Principal at issuance	[2]	$ 538
Gross proceeds before issuance costs	[2]	$ 350
Warrants at issued (common stock)	[2]	258,584
Maturity Date	[2]	Mar. 20, 2026
Conversion price		$ 1.625	[2]	0.0615	[2]	0.0845	0.8125	[2]	0.0158	[2]	2.50	[2]
April 2023 Notes [Member]
Short-Term Debt [Line Items]
Principal at issuance		$ 769
Gross proceeds before issuance costs		$ 500
Warrants at issued (common stock)		615,384
Maturity Date		Mar. 06, 2026
Conversion price				0.0615		0.0845	$ 0.8125		0.0158	[2]	1.25
July 2023 Notes [Member]
Short-Term Debt [Line Items]
Principal at issuance		$ 1,500
Gross proceeds before issuance costs		$ 975
Warrants at issued (common stock)		1,200,000
Maturity Date		Mar. 06, 2026
Conversion price				0.0615		0.0845			0.0158	[2]	1.25
August 2023 Notes [Member]
Short-Term Debt [Line Items]
Principal at issuance		$ 1,000
Gross proceeds before issuance costs		$ 650
Warrants at issued (common stock)		799,999
Maturity Date		Aug. 04, 2026
Conversion price				0.0615		0.0845			$ 0.0158	[2]	1.25
September 2023 Notes [Member]
Short-Term Debt [Line Items]
Principal at issuance	[3]	$ 2,885
Gross proceeds before issuance costs	[3]	$ 1,875
Warrants at issued (common stock)	[3]	26,997,041
Maturity Date	[3]	Sep. 26, 2026
Conversion price	[3]	$ 0.0158		$ 0.0615		$ 0.13					$ 0.13
Senior Subordinated Notes [Member]
Short-Term Debt [Line Items]
Principal at issuance		$ 10,985
Gross proceeds before issuance costs		$ 7,140
Warrants at issued (common stock)		31,133,776
[1]Warrants include 99,692 43,200 22,189,349 0.13 4,807,692 0.001

Schedule of SSNs and Warrants_2

Schedule of SSNs and Warrants (Details) (Parenthetical) - $ / shares	Mar. 31, 2024	Sep. 30, 2023	Mar. 31, 2023	Feb. 28, 2023	May 31, 2022
Short-Term Debt [Line Items]
Warrants					894,194
Warrants exercise price	$ 2.42
Placement Agent [Member] | December Two Thousand Twenty Two To September Two Thousand Twenty Three [Member]
Short-Term Debt [Line Items]
Number of shares to purchase capital stock			43,200	99,692
Placement Agent [Member] | December Two Thousand Twenty Two To September Two Thousand Twenty Three [Member] | Series A Preferred Stock [Member]
Short-Term Debt [Line Items]
Warrants		22,189,349
Warrants exercise price		$ 0.13
Placement Agent [Member] | December Two Thousand Twenty Two To September Two Thousand Twenty Three [Member] | Series B Preferred Stock [Member]
Short-Term Debt [Line Items]
Warrants		4,807,692
Warrants exercise price		$ 0.001

Debt (Details Narrative)

Debt (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands

1 Months Ended

3 Months Ended

12 Months Ended

Oct. 01, 2023

Sep. 08, 2023

Mar. 07, 2023

Dec. 19, 2022

Sep. 15, 2022

Apr. 04, 2022

Mar. 21, 2022

Nov. 20, 2021

Oct. 14, 2020

Jun. 09, 2020

Apr. 24, 2020

Sep. 30, 2023

Mar. 31, 2024

Mar. 31, 2023

Dec. 31, 2023

Apr. 19, 2024

Feb. 26, 2024

Dec. 21, 2023

Aug. 07, 2023

Jun. 30, 2023

Dec. 31, 2022

Sep. 30, 2022

May 31, 2022

Apr. 23, 2020

Debt Instrument [Line Items]

Warrant exercise price per share

$ 2.42

Interest expense

$ 564

$ 565

Proceeds from issuance of sale of equity

$ 50,000

Debt covenant, cumulative net sales requirement

$ 100,000

Exercise price

$ 0.0158

Debt instrument periodic payment

$ 92,700

Cumulative net sales

$ 100,000

Accrued interest percentage

10%

Interest revenue expenses net

$ 1,000

Debt and interest payment description

The cash payments will be determined based upon the quarterly global net revenue of Phexxi such that if the global net revenue is less than or equal to $5.0 million, the Company will pay 3% of such global net revenues; if the global net revenue is over $5.0 million and less than or equal to $7.0 million, the Company will continue to pay 3% on net revenue up to $5.0 million and 4% on the net revenue over $5.0 million; and if the global net revenue is over $7.0 million, the Company will pay 3% on the net revenue up to $5.0 million, 4% on the net revenue over $5.0 million up to $7.0 million, and 5% on net revenue over $7.0 million. The cash payments were payable beginning in the fourth quarter of 2023. Regardless of the percentage paid, the quarterly cash payment amounts, along with the $1.0 million upfront payment, will be deducted from the Repurchase Price as Applicable Reductions.

Gain on extinguishment of debt

$ 1,120

$ 75,300

Revalued amount extinguishment of debt amount

$ 73,200

Common stock, par value (in usd per share)

$ 0.0001

$ 0.0001

$ 0.0001

[custom:DebtInstrumentRedemptionPremiumInEventOfDefault-0]

25%

Warrants to purchase up

894,194

Series F One Shares [Member]

Debt Instrument [Line Items]

Warrants outstanding

22,280

Common Stock [Member]

Debt Instrument [Line Items]

Warrants to purchase up

9,972,074

Warrants outstanding

613

Subsequent Event [Member]

Debt Instrument [Line Items]

Conversion price

$ 0.0154

June 2022 Baker Warrants [Member]

Debt Instrument [Line Items]

Warrants purchase

582,886

Warrant exercise price per share

$ 93.75

Baker Warrants [Member]

Debt Instrument [Line Items]

Warrant exercise price per share

$ 0.0158

Baker Bros. Notes [Member]

Debt Instrument [Line Items]

[custom:ClassOfWarrantOrRightVestingTerm]

5 years

Debt instrument, term

2 years

Conversion price

$ 4,575

Conversion price as a percentage of lowest stock price

115%

Conversion price threshold percentage

100%

Short-term convertible notes payable

$ 12,500

$ 13,252

$ 14,731

$ 13,500

Accrued interest

102,000

Baker Bros. Notes [Member] | Convertible Notes Payable [Member]

Debt Instrument [Line Items]

Debt instrument, face amount

$ 25,000

Debt instrument, term

5 years

Debt instrument conversion rate

10%

Debt instrument interest rate effective percent

10%

Interest expense

2,500

$ 1,400

Written notice period

10 days

Debt instrument, benchmark price per share

$ 9,356.25

Conversion price

$ 4,575

Baker Bros. Notes [Member] | Convertible Notes Payable [Member] | Debt Instrument, Redemption, Period Two [Member]

Debt Instrument [Line Items]

Debt instrument, redemption price, percentage

100%

Baker Bros. Notes [Member] | Convertible Notes Payable [Member] | Debt Instrument, Redemption, Period One [Member]

Debt Instrument [Line Items]

Debt instrument, redemption price, percentage

110%

Baker Bros. Notes [Member] | Baker Second Closing Notes [Member]

Debt Instrument [Line Items]

Debt instrument, face amount

$ 25,000

Warrants purchase

2,731

Warrant exercise price per share

$ 4,575

Second Baker Amendment [Member]

Debt Instrument [Line Items]

Conversion price

$ 725.81

Debt covenant, cumulative net sales requirement

100,000

Conversion price threshold percentage

100%

Proceeds from issuance of common stock

$ 20,000

Second Baker Amendment [Member] | Baker Warrants [Member]

Debt Instrument [Line Items]

Warrant exercise price per share

$ 93.75

Third Baker Amendment [Member]

Debt Instrument [Line Items]

Conversion price

$ 26.25

Secured Creditor Forbearance Agreement [Member]

Debt Instrument [Line Items]

Debt instrument indebtedness amount

$ 5,000

Old Baker Notes [Member]

Debt Instrument [Line Items]

Notes payable fair value

15,600

Accumulated other comprehensive income

73,200

Short-term Convertible Notes [Member]

Debt Instrument [Line Items]

Short-term convertible notes payable

$ 12,300

Adjuvant Notes [Member]

Debt Instrument [Line Items]

Debt instrument interest rate effective percent

8.80%

Conversion price

$ 678.49

$ 0.0158

Conversion price as a percentage of lowest stock price

100%

Short-term convertible notes payable

$ 29,101

28,537

Debt conversion, converted instrument shares issued

1,842,275,987

Adjuvant Notes [Member] | Convertible Notes Payable [Member]

Debt Instrument [Line Items]

Debt instrument, face amount

$ 25,000

Debt instrument, term

5 years

Debt instrument conversion rate

7.50%

Conversion price

$ 26.25

$ 6,843.75

Debt covenant, cumulative net sales requirement

$ 100,000

Beneficial ownership limitation percentage

4.99%

Beneficial ownership limitation percentage

19.99%

Common stock, par value (in usd per share)

$ 0.0001

Debt instrument weighted average price per share

$ 18,750

$ 18,750

Debt instrument weighted average period

30 days

Debt instrument convertible exchange percentage

10%

Debt Conversion, Converted Instrument, Amount

$ 2,900

Debt conversion converted instrument amount

109,842

Restricted Cash

$ 25,000

Convertible debt

$ 29,100

28,500

Convertible debt, current principal amount

22,500

$ 22,500

Convertible debt, current, accrued interest

$ 6,600

$ 6,100

8.0% Senior Subordinated Notes Due 2025 Issued December 2022 [Member]

Debt Instrument [Line Items]

[custom:DebtInstrumentRedemptionPremiumInEventOfDefault-0]

32.50%

8.0% Senior Subordinated Notes Due 2025 Issued December 2022 [Member] | Unsecured Debt [Member]

Debt Instrument [Line Items]

Debt instrument interest rate stated percent

8%

[custom:DebtInstrumentInterestRateInEventOfDefault-0]

12%

Schedule of Inventories (Detail

Schedule of Inventories (Details) - USD ($) $ in Thousands		Mar. 31, 2024	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	[1]	$ 526	$ 520
Work in process			386
Finished goods	[1]	780	791
Total		$ 1,306	$ 1,697
[1]The raw materials and finished goods balances included a combined estimated reserve on obsolescence and excess inventory which might not be sold prior to expiration of $ 0.2 0.3 1.3

Schedule of Inventories (Deta_2

Schedule of Inventories (Details) (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Inventory adjustments	$ 0.3	$ 0.2
Inventory write-down	$ 1.3

Schedule of Prepaid and Other C

Schedule of Prepaid and Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Insurance	$ 314	$ 777
Research & development	13	13
Other	295	405
Total	$ 622	$ 1,195

Schedule of Property and Equipm

Schedule of Property and Equipment Net (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Property and equipment gross	$ 1,889	$ 2,389
Less: accumulated depreciation	(689)	(1,186)
Total, net	1,200	1,203
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment gross	$ 586	586
Useful Life	5 years
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment gross	$ 151	647
Computer Equipment and Software [Member]
Property, Plant and Equipment [Line Items]
Useful Life	3 years
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment gross	$ 1,152	$ 1,156

Schedule of Accrued Expenses (D

Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Clinical trial related costs	$ 2,498	$ 2,498
Accrued royalty	1,336	1,146
Other	741	583
Total	$ 4,575	$ 4,227

Balance Sheet Details (Details

Balance Sheet Details (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Depreciation expense	$ 12	$ 245

Schedule of Fair Value of Finan

Schedule of Fair Value of Financial Liabilities (Details) - USD ($) $ in Thousands		Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities		$ 4,310	$ 1,926
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities		4,310	1,926
Convertible Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount		133,771	131,337
Unamortized Issuance Costs			(27)
Accrued Interest		6,601	6,064
Net carrying amount		140,372	137,374
Fair value amount		13,252	14,731
Unamortized Issuance Costs			27
Baker Bros. Notes [Member] | Convertible Debt [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount	[1],[2]	101,974	99,460
Unamortized Issuance Costs	[1],[2]
Accrued Interest	[1],[2]
Net carrying amount	[1],[2]	101,974	99,460
Fair value amount	[1],[2]	12,260	13,510
Unamortized Issuance Costs	[1],[2]
Adjuvant Notes [Member] | Convertible Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unamortized Issuance Costs	[3]		(27)
Accrued Interest	[3]	6,601	6,064
Unamortized Issuance Costs	[3]		27
Adjuvant Notes [Member] | Convertible Debt [Member] | Reported Value Measurement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Net carrying amount	[3]	29,101	28,537
Adjuvant Notes [Member] | Convertible Debt [Member] | Estimate of Fair Value Measurement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value amount	[3]
Adjuvant Notes [Member] | Convertible Debt [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount	[1],[2]	22,500
Fair value amount	[1],[2]		22,500
December 2022 Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount		2,308
December 2022 Notes [Member] | Convertible Debt [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount	[2]	959	940
Unamortized Issuance Costs	[2]
Accrued Interest	[2]
Net carrying amount	[2]	959	940
Fair value amount	[2]	103	118
Unamortized Issuance Costs	[2]
February 2023 Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount	[4]	1,385
February 2023 Notes [Member] | Convertible Debt [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount	[2]	924	905
Unamortized Issuance Costs	[2]
Accrued Interest	[2]
Net carrying amount	[2]	924	905
Fair value amount	[2]	99	118
Unamortized Issuance Costs	[2]
March 2023 Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount		600
March 2023 Notes [Member] | Convertible Debt [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount	[2]	1,189	1,204
Unamortized Issuance Costs	[2]
Accrued Interest	[2]
Net carrying amount	[2]	1,189	1,204
Fair value amount	[2]	127	157
Unamortized Issuance Costs	[2]
April 2023 Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount		769
April 2023 Notes [Member] | Convertible Debt [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount	[2]	832	816
Unamortized Issuance Costs	[2]
Accrued Interest	[2]
Net carrying amount	[2]	832	816
Fair value amount	[2]	89	106
Unamortized Issuance Costs	[2]
July 2023 Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount		1,500
July 2023 Notes [Member] | Convertible Debt [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount	[2]	1,335	1,534
Unamortized Issuance Costs	[2]
Accrued Interest	[2]
Net carrying amount	[2]	1,335	1,534
Fair value amount	[2]	142	202
Unamortized Issuance Costs	[2]
August 2023 Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount		1,000
August 2023 Notes [Member] | Convertible Debt [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount	[2]	1,054	1,033
Unamortized Issuance Costs	[2]
Accrued Interest	[2]
Net carrying amount	[2]	1,054	1,033
Fair value amount	[2]	112	136
Unamortized Issuance Costs	[2]
September 2023 Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount	[5]	2,885
September 2023 Notes [Member] | Convertible Debt [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount	[2]	3,004	2,945
Unamortized Issuance Costs	[2]
Accrued Interest	[2]
Net carrying amount	[2]	3,004	2,945
Fair value amount	[2]	320	384
Unamortized Issuance Costs	[2]
[1]The Baker Notes principal amount includes $ 16.9 13.7 99,692 22,189,349 0.13 4,807,692 0.001

Schedule of Fair Value of Fin_2

Schedule of Fair Value of Financial Liabilities (Details) (Parenthetical) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Baker Notes [Member] | Convertible Debt [Member]
Short-Term Debt [Line Items]
Interest paid in kind	$ 16.9	$ 13.7

Schedule of Change in Fair Valu

Schedule of Change in Fair Value of Level 3 Financial Liabilities (Details) - Fair Value, Inputs, Level 3 [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Long-Term Debt [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 14,731	$ 39,416
Extinguishment/conversion	(13,545)
Initial liability at issuance	12,390	12
Change in fair value presented in the consolidated statements of operations	(324)	(15,460)
Ending balance	13,252	23,807
Change in fair value presented in the consolidated statements of operations		(161)
Long-Term Debt [Member] | Baker Notes Assigned To Aditxt Notes [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	13,510	39,260
Extinguishment/conversion	(13,510)
Initial liability at issuance	12,390
Change in fair value presented in the consolidated statements of operations	(130)	(15,460)
Ending balance	12,260	23,800
Change in fair value presented in the consolidated statements of operations
Long-Term Debt [Member] | Total Offerings [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	1,221	156
Extinguishment/conversion	(35)
Initial liability at issuance		12
Change in fair value presented in the consolidated statements of operations	(194)
Ending balance	992	7
Change in fair value presented in the consolidated statements of operations		(161)
Derivative Financial Instruments, Liabilities [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	1,926	1,676
Initial liability at issuance	3,275	83
Change in fair value presented in the consolidated statements of operations	(802)	(1,451)
Ending balance	4,310	122
Exercises	(89)	(186)
Derivative Financial Instruments, Liabilities [Member] | Rights [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	1,926	1,095
Initial liability at issuance	3,275	77
Change in fair value presented in the consolidated statements of operations	(802)	(886)
Ending balance	4,310	106
Exercises	(89)	(180)
Derivative Financial Instruments, Liabilities [Member] | Derivative Liability Convertible Preferred Stock [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance		1
Initial liability at issuance
Change in fair value presented in the consolidated statements of operations	(1)
Ending balance
Exercises
Derivative Financial Instruments, Liabilities [Member] | May 2022 Public Offering Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance		303
Initial liability at issuance
Change in fair value presented in the consolidated statements of operations		(291)
Ending balance		6
Exercises		(6)
Derivative Financial Instruments, Liabilities [Member] | June 2022 Baker Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance		170
Initial liability at issuance
Change in fair value presented in the consolidated statements of operations		(167)
Ending balance		3
Exercises
Derivative Financial Instruments, Liabilities [Member] | December 2022 Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance		107
Initial liability at issuance
Change in fair value presented in the consolidated statements of operations		(106)
Ending balance
Exercises
Derivative Financial Instruments, Liabilities [Member] | February and March 2023 Notes [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance
Initial liability at issuance		6
Change in fair value presented in the consolidated statements of operations
Ending balance		6
Exercises

Fair Value of Financial Instr_3

Fair Value of Financial Instruments (Details Narrative) $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)
Baker Bros. Notes [Member] | Measurement Input Royalty Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt instrument, measurement input	0.050
Baker Bros. Notes [Member] | Measurement Input, Discount Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt instrument, measurement input	0.150
Senior Subordinated Notes [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Change in fair value of financial instruments	$ 0.2	$ 1.6

Schedule of Lease Cost (Details

Schedule of Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Loss Contingencies [Line Items]
Operating lease expense	$ 56	$ 456
Research and Development Expense [Member]
Loss Contingencies [Line Items]
Operating lease expense	1	66
Selling and Marketing Expense [Member]
Loss Contingencies [Line Items]
Operating lease expense	52	159
General and Administrative Expense [Member]
Loss Contingencies [Line Items]
Operating lease expense	$ 3	$ 231

Schedule of Lease Term and Disc

Schedule of Lease Term and Discount Rate (Details)	Mar. 31, 2024	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Weighted Average Remaining Lease Term (in years)	7 months 24 days	9 months
Weighted Average Discount Rate	12%	12%

Schedule of Operating Lease Mat

Schedule of Operating Lease Maturities (Details) $ in Thousands	Mar. 31, 2024 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Remainder of 2024 (9 months)	$ 56
Year ending December 31, 2025	11
Total lease payments	67
Less imputed interest	(8)
Total	$ 59

Schedule of Supplement Cash Out

Schedule of Supplement Cash Outflows in Operating Leases (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Operating cash outflows in operating leases	$ 64	$ 610

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative)			1 Months Ended		3 Months Ended
	May 27, 2022 USD ($) ft²	Jan. 01, 2021 USD ($)	Jun. 30, 2023 USD ($)	Sep. 30, 2022	Mar. 31, 2024 USD ($) Integer	Mar. 31, 2023 USD ($)	Dec. 31, 2023 USD ($)	Mar. 20, 2023 USD ($)	Apr. 14, 2020 USD ($) ft²	Dec. 31, 2019	Oct. 03, 2019 USD ($) ft²
Loss Contingencies [Line Items]
Number of leased vehicles | Integer					20
Restricted cash					$ 689,000	$ 895,000	$ 580,000
Square footage | ft²									8,816		24,474
Operating lease right-of-use assets					59,000		106,000	$ 3,300,000
Operating lease liabilities					4,000		8,000	4,200,000
Gain on termination of lease			$ 200,000
Company area (in square feet) | ft²	16,637
Lease expenses	$ 100,000
Lease percentage	3.50%
Sublease gross income						300,000
Purchase obligation, purchases during the period					$ 0	0
Accounts payable, trade							2,100,000
Percentage of accounts payable trade					94%
Accrued expenses					$ 4,575,000		4,227,000
Rush License Agreement [Member]
Loss Contingencies [Line Items]
Royalty cost					200,000	$ 200,000
Accrued expenses					1,300,000		$ 1,100,000
Rush License Agreement [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Royalty cost		$ 100,000
Rush License Agreement [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Royalty cost		$ 100,000
Letter of Credit [Member]
Loss Contingencies [Line Items]
Security deposit									$ 50,000		$ 800,000
Vehicles [Member] | Securities Deposit [Member]
Loss Contingencies [Line Items]
Restricted cash					$ 300,000
Building and Building Improvements [Member] | Letter of Credit [Member]
Loss Contingencies [Line Items]
Restricted cash								$ 800,000
Lease Contract Term One [Member]
Loss Contingencies [Line Items]
Lessee, Operating Lease, Term of Contract				24 months
Lessee operating lease extended lease term				12 months
Lease Contract Term One [Member] | Vehicles [Member]
Loss Contingencies [Line Items]
Lessee, Operating Lease, Term of Contract										24 months
Lease Contract Term [Member] | Vehicles [Member]
Loss Contingencies [Line Items]
Lessee, Operating Lease, Term of Contract										36 months

Schedule of Warrants (Details)

Schedule of Warrants (Details) - $ / shares	Sep. 27, 2023	Aug. 04, 2023	Jul. 03, 2023	Apr. 05, 2023	Mar. 20, 2023	Feb. 17, 2023	Dec. 21, 2022	Jun. 28, 2022	May 24, 2022	May 04, 2022	Mar. 01, 2022	Jan. 13, 2022	Jun. 09, 2020	Apr. 24, 2020	Jun. 10, 2019	Apr. 11, 2019	May 24, 2018	Jun. 11, 2014	Mar. 31, 2024	Apr. 08, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Class of warrant or right outstanding																			20,807,543,000
Exercise price																			$ 2.42
Common Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Class of warrant or right outstanding	12,721,893		349,463	369,231	258,584	130,461	49,227	582,886	894,194	6,666	8,303	8,003	1,092	1,639	1,480	888	451	4		615,384
Exercise price	$ 0.0158	$ 0.0158	$ 0.0158	$ 0.0158	$ 0.0158	$ 0.0158	$ 0.0158	$ 0.0158	$ 0.0158	$ 309.56	$ 897.56	$ 735	$ 0.0158	$ 0.0158	$ 11,962.50	$ 11,962.50	$ 14,062.50	$ 6,918.75
Warrants exercise period	September 27, 2023 to September 27, 2028	August 4, 2023 to August 4, 2028	July 3, 2023 to July 3, 2028	April 5, 2023 to April 5, 2028	March 20, 2023 to March 20, 2028	February 17, 2023 to February 17, 2028	December 21, 2022 to December 21, 2027	May 24, 2022 to June 28, 2027	May 24, 2022 to May 24, 2027	May 4, 2022 to May 4, 2027	March 1, 2022 to March 1, 2027	March 1, 2022 to March 1, 2027	June 9, 2020 to June 9, 2025	April 24, 2020 to April 24, 2025	December 10, 2019 to June 10, 2026	October 11, 2019 to April 11, 2026	May 24, 2018 to May 24 2025	June 11, 2014 to June 11, 2024
Prefunded Common Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Class of warrant or right outstanding	4,807,694
Exercise price	$ 0.0010
Warrants exercise period	September 27, 2023 to September 27, 2028

Summary of Common Stock Reserve

Summary of Common Stock Reserved for Future Issuance (Details)	Mar. 31, 2024 shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock reserved upon exercise of stock options outstanding	3,747
Common stock reserved upon exercise of common stock warrants	10,598,205
Common stock reserved for the exercise of purchase rights	722,646,377
Common stock reserved for conversion of convertible notes	148,541,458
Number of shares available for grant	33,750,860
Common stock capital shares reserved for future issuance	915,547,554	[1]
Employee Stock Purchase Plan 2019 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares available for grant	509
Amended and Restated 2014 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares available for grant	5,789
Inducement Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares available for grant	609
[1]The potentially dilutive securities in Note 2 – Summary of Significant Accounting Policies includes all potentially dilutive securities that are not included in the diluted EPS as per U.S. GAAP, whereas the total common stock reserved for future issuance in the table above includes the shares that must legally be reserved based on the applicable instruments’ agreements.

Convertible and Redeemable Pr_3

Convertible and Redeemable Preferred Stock and Stockholders’ Deficit (Details Narrative) $ / shares in Units, $ in Millions

1 Months Ended

3 Months Ended

12 Months Ended

Aug. 07, 2023 USD ($) $ / shares shares

Sep. 15, 2022 USD ($) shares

Jun. 30, 2022 $ / shares shares

Mar. 31, 2024 USD ($) Integer $ / shares shares

Mar. 31, 2023 USD ($) Integer shares

Dec. 31, 2023 USD ($) $ / shares shares

Apr. 19, 2024 $ / shares

Dec. 21, 2023 shares

Dec. 11, 2023 $ / shares shares

Dec. 31, 2022 $ / shares

Dec. 16, 2022 $ / shares shares

May 31, 2022 $ / shares shares

Dec. 15, 2021 $ / shares shares

Apr. 30, 2020 $ / shares shares

Class of Warrant or Right [Line Items]

Warrants exercise price | $ / shares

$ 2.42

Common stock warrant outstanding

894,194

Common stock, par value | $ / shares

$ 0.0001

$ 0.0001

$ 0.0001

Class of warrant or right, number of securities called by warrants or rights

20,807,543,000

Common stock shares

9,972,074

Preferred stock, shares authorized

5,000,000

5,000,000

5,000,000

Preferred stock, par value | $ / shares

$ 0.0001

$ 0.0001

$ 0.0001

Shares authorized

2,300

Redemption premium percentage

25%

Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock | $

$ 1.8

Warrants to purchase up

10,598,205

Preferred stock, shares issued

0

0

Common stock, shares authorized

3,000,000,000

3,000,000,000

3,000,000,000

Common stock capital share reserved for future issuance

722,646,377

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount

[1]

5,513,316,258

35,466,940

Rights [Member]

Class of Warrant or Right [Line Items]

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount

1,530,645,242

14,238,827

Adjuvant and May 2022 Notes [Member]

Class of Warrant or Right [Line Items]

Aggregate purchase rights

942,080

Purchase rights | $

$ 24.7

Series F-1 [Member]

Class of Warrant or Right [Line Items]

Common stock shares

613

Series E1 Convertible Preferred Stock [Member]

Class of Warrant or Right [Line Items]

Conversion price | $ / shares

$ 0.40

$ 0.0158

$ 0.0635

Preferred stock, shares authorized

95,000

Preferred stock, par value | $ / shares

$ 0.0001

$ 0.0001

Debt Conversion, Converted Instrument, Amount | $

$ 1.8

Series F One Shares [Member]

Class of Warrant or Right [Line Items]

Warrants outstanding

22,280

Series F-1 Common Stock [Member]

Class of Warrant or Right [Line Items]

Warrants to purchase up

9,972,074

Series F-1 Convertible and Redeemable Preferred Stock [Member]

Class of Warrant or Right [Line Items]

Temporary Equity, Shares Outstanding

22,280

22,280

Preferred stock, convertible shares issuable

21,667

Series D Non-Convertible Preferred Stock [Member]

Class of Warrant or Right [Line Items]

Preferred stock, shares authorized

70

Preferred stock, par value | $ / shares

$ 0.0001

Preferred stock voting right power percentage

1%

Preferred stock, shares issued

70

Warrant [Member]

Class of Warrant or Right [Line Items]

Warrants exercise price | $ / shares

$ 0.0158

Common Stock [Member]

Class of Warrant or Right [Line Items]

Common stock warrant outstanding

9,972,074

Warrants outstanding

613

Common Stock [Member] | Minimum [Member]

Class of Warrant or Right [Line Items]

Warrants exercise price | $ / shares

0.13

Common Stock [Member] | Maximum [Member]

Class of Warrant or Right [Line Items]

Warrants exercise price | $ / shares

$ 1.25

Preferred Stock [Member] | Series E1 Convertible Preferred Stock [Member]

Class of Warrant or Right [Line Items]

Temporary Equity, Shares Outstanding

1,800

Preferred Stock [Member] | Series F-1 Convertible and Redeemable Preferred Stock [Member]

Class of Warrant or Right [Line Items]

Temporary Equity, Shares Outstanding

22,280

22,280

Underwritten Public Offering [Member]

Class of Warrant or Right [Line Items]

Number of shares to purchase capital stock

362,640

Warrants exercise price | $ / shares

$ 93.75

IPO [Member]

Class of Warrant or Right [Line Items]

Number of shares to purchase capital stock

205,360

Warrants exercise price | $ / shares

$ 93.63

Subsequent Event [Member]

Class of Warrant or Right [Line Items]

Conversion price | $ / shares

$ 0.0154

Baker Warrants [Member]

Class of Warrant or Right [Line Items]

Warrants exercise price | $ / shares

$ 0.0158

June 2022 Baker Warrants [Member]

Class of Warrant or Right [Line Items]

Number of shares to purchase capital stock

582,886

Warrants exercise price | $ / shares

$ 93.75

$ 0.0158

Warrants and rights outstanding, term

5 years

5 years

Common stock, par value | $ / shares

$ 0.0001

June 2022 Baker Warrants [Member] | Minimum [Member]

Class of Warrant or Right [Line Items]

Beneficial ownership limitation percentage

4.99%

June 2022 Baker Warrants [Member] | Maximum [Member]

Class of Warrant or Right [Line Items]

Beneficial ownership limitation percentage

19.99%

Baker Bros Purchase Agreement [Member]

Class of Warrant or Right [Line Items]

Number of shares to purchase capital stock

2,732

Warrants exercise price | $ / shares

$ 4,575

Security Purchase Agreement [Member]

Class of Warrant or Right [Line Items]

Number of shares to purchase capital stock

1,152,122

Warrants exercise price | $ / shares

$ 2.50

Class of warrant or right, number of securities called by warrants or rights

20,807,543

Security Purchase Agreement [Member] | Warrant [Member]

Class of Warrant or Right [Line Items]

Warrants exercise price | $ / shares

$ 0.0158

Security Purchase Agreement [Member] | Common Stock [Member] | Minimum [Member]

Class of Warrant or Right [Line Items]

Class of warrant or right, number of securities called by warrants or rights

22,189,349

Security Purchase Agreement [Member] | Common Stock [Member] | Maximum [Member]

Class of Warrant or Right [Line Items]

Class of warrant or right, number of securities called by warrants or rights

2,615,383

Exchange Agreements [Member]

Class of Warrant or Right [Line Items]

Debt Instrument, Convertible, Number of Equity Instruments | Integer

1,145,333,158

10,467,332

Loss on issuance of financial instruments | $

$ 3.3

$ 0.1

Common stock capital share reserved for future issuance

17,725,000

[1]The potentially dilutive securities in the table above include all potentially dilutive securities that are not included in the diluted EPS as per U.S. GAAP, whereas the total common stock reserved for future issuance in Note 8 – Stockholders’ Deficit

Schedule of Stock-based Compens

Schedule of Stock-based Compensation Expense Related to Stock Options (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 237	$ 417
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	16	40
Selling and Marketing Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	35	57
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 186	$ 320

Stock-based Compensation (Detai

Stock-based Compensation (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross	0	0
Employee Benefits and Share-Based Compensation	$ 900,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition	1 year 4 months 24 days
Employee Stock [Member] | Employee Stock Purchase Plan 2019 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent	85%
[custom:EmployeeStockPurchasePlanMaximumStockValueAvailableForPurchaseDenominator-0]	$ 25,000
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation expense	$ 0

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands				1 Months Ended	3 Months Ended
	Jul. 01, 2024	Jun. 17, 2024	May 02, 2024	May 15, 2024	Mar. 31, 2024	Mar. 31, 2023	Apr. 19, 2024	Dec. 31, 2023	Dec. 15, 2021
Subsequent Event [Line Items]
Preferred stock, par value					$ 0.0001			$ 0.0001	$ 0.0001
Number of shares, value					$ 89	$ 180
Stock issued during period value conversion of convertible securities					$ 35
Subsequent Event [Member]
Subsequent Event [Line Items]
Conversion price							$ 0.0154
Equity instrument consideration shares issued				6,150,000
Stock issued during period value conversion of convertible securities				$ 100
Stock issued during period shares conversion of convertible securities				7,200,000
Subsequent Event [Member] | Series F 1 Preferred Stock [Member]
Subsequent Event [Line Items]
Preferred stock, par value			$ 0.0001
Number of shares issued			1,000
Number of shares issued			2,500,000,000
Parent capital raise	$ 1,000
Subsequent Event [Member] | Series F 1 Preferred Stock [Member] | Maximum [Member]
Subsequent Event [Line Items]
Number of shares, value			$ 2,500
Parent capital raise		$ 1,500
Fourth Amendment Merger Agreement [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Initial payment			$ 1,000